

Data Set Name: adm.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	PROTSEG	Char	1	\$1.	\$1.	Protocol Segment
4	DISCPTST	Char	1	\$X1592X.	\$1.	Pt Status at Discharge
5	PHSPREAS	Char	2	\$X55670X.	\$2.	Prim Reason for Re-Admit
6	ADM4SPEC	Char	50	\$50.	\$50.	Prim Reason Organ Spec
7	ADM1SPEC	Char	50	\$50.	\$50.	Primary Reason Other Spec
8	REASGVHD	Char	1	\$X4602X.	\$1.	GVHD
9	REASRLPS	Char	1	\$X4602X.	\$1.	Relapse/Progression
10	REASGF	Char	1	\$X4602X.	\$1.	Graft Failure
11	REASINF	Char	1	\$X4602X.	\$1.	Infection
12	REASFVR	Char	1	\$X4602X.	\$1.	Fever
13	REASSZR	Char	1	\$X4602X.	\$1.	Seizure
14	REASGIBL	Char	1	\$X4602X.	\$1.	Bleeding
15	REASDRH	Char	1	\$X4602X.	\$1.	Diarrhea
16	REASNV	Char	1	\$X4602X.	\$1.	Nausea/Vomiting
17	REASORGF	Char	1	\$X4602X.	\$1.	Organ Failure
18	ADM3SPEC	Char	50	\$50.	\$50.	Specify Organ
19	REASTRAM	Char	1	\$X4602X.	\$1.	Trauma
20	REASPSYC	Char	1	\$X4602X.	\$1.	Psychiatric
21	REASMALG	Char	1	\$X4602X.	\$1.	Secondary Malignancy
22	REASPROC	Char	1	\$X4602X.	\$1.	Procedure/Treatment
23	REASTRMB	Char	1	\$X4602X.	\$1.	Thrombosis/Embolism
24	REASOTHR	Char	1	\$X4602X.	\$1.	Other
25	ADM2SPEC	Char	50	\$50.	\$50.	Other Reason Specify
26	ADMCENTR	Char	1	\$X1651X.	\$1.	Re-Admission Center
27	ADMITDT_DAYS	Num	8			Date of Admission (recode: number of days after consent)
28	DISCHDT_DAYS	Num	8			Date of Discharge (recode: number of days after consent)

Data Set Name: ae.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	PROTSEG	Char	1	\$1.	\$1.	Protocol Segment
4	ADVENT	Char	35	\$35.	\$35.	Event description
5	AVSTATUS	Char	1	\$X5109X.	\$1.	Activation status
6	AESPEC1	Char	50	\$50.	\$50.	Activation status specify
7	AVWGHTKG	Num	8	7.1	7.1	Weight in kilograms
8	AVEXPECT	Char	1	\$X1457X.	\$1.	Expected
9	AVEVENT	Char	1	\$X4680X.	\$1.	Severity of event
10	AVRELTXP	Char	2	\$X34971X.	\$2.	Related to transplant
11	AVRELBOR	Char	2	\$X34971X.	\$2.	Related to bortezomib
12	AVRELMNT	Char	2	\$X34971X.	\$2.	Related to maintenance
13	AVETIOL	Char	1	\$X10839X.	\$1.	Alternative etiology
14	AVEFFECT	Char	1	\$X10840X.	\$1.	Effect on therapy/interven
15	AVOUTCOM	Char	1	\$X10841X.	\$1.	Outcome of the event
16	AVASSOCI	Char	1	\$X4685X.	\$1.	Event associated with
17	SEMEDHXS	Char	1	\$X1457X.	\$1.	Relevant past med hx
18	RCVSP	Char	1	\$X1457X.	\$1.	Receiving study products
19	SPNAME1	Char	20	\$20.	\$20.	Study product name 1
20	SP1DOSE	Char	12	\$12.	\$12.	Study product 1 dose
21	SP1ROUTE	Char	10	\$10.	\$10.	Study product 1 route
22	SP1SCHED	Char	12	\$12.	\$12.	Study product 1 schedule
23	SP1REASO	Char	25	\$25.	\$25.	Study product 1 reason
24	SPNAME2	Char	20	\$20.	\$20.	Study product name 2
25	SP2DOSE	Char	12	\$12.	\$12.	Study product 2 dose
26	SP2ROUTE	Char	10	\$10.	\$10.	Study product 2 route
27	SP2SCHED	Char	12	\$12.	\$12.	Study product 2 schedule
28	SP2REASO	Char	25	\$25.	\$25.	Study product 2 reason
29	SPNAME3	Char	20	\$20.	\$20.	Study product name 3
30	SP3DOSE	Char	12	\$12.	\$12.	Study product 3 dose
31	SP3ROUTE	Char	10	\$10.	\$10.	Study product 3 route
32	SP3SCHED	Char	12	\$12.	\$12.	Study product 3 schedule
33	SP3REASO	Char	25	\$25.	\$25.	Study product 3 reason
34	SPNAME4	Char	20	\$20.	\$20.	Study product name 4
35	SP4DOSE	Char	12	\$12.	\$12.	Study product 4 dose
36	SP4ROUTE	Char	10	\$10.	\$10.	Study product 4 route

Num	Variable	Type	Len	Format	Informat	Label
37	SP4SCHED	Char	12	\$12.	\$12.	Study product 4 schedule
38	SP4REASO	Char	25	\$25.	\$25.	Study product 4 reason
39	RCVCONMD	Char	1	\$X1457X.	\$1.	Receiving con meds
40	CONMED1	Char	30	\$30.	\$30.	Concomitant Medication 1
41	CM1DOSE	Char	20	\$20.	\$20.	Con med 1 dose/route/sche
42	CM1INDIC	Char	1	\$X4687X.	\$1.	Con med 1 indication
43	CONMED2	Char	30	\$30.	\$30.	Concomitant Medication 2
44	CM2DOSE	Char	20	\$20.	\$20.	Con med 2 dose/route/sche
45	CM2INDIC	Char	1	\$X4687X.	\$1.	Con med 2 indication
46	CONMED3	Char	30	\$30.	\$30.	Concomitant Medication 3
47	CM3DOSE	Char	20	\$20.	\$20.	Con med 3 dose/route/sche
48	CM3INDIC	Char	1	\$X4687X.	\$1.	Con med 3 indication
49	CONMED4	Char	30	\$30.	\$30.	Concomitant Medication 4
50	CM4DOSE	Char	20	\$20.	\$20.	Con med 4 dose/route/sche
51	CM4INDIC	Char	1	\$X4687X.	\$1.	Con med 4 indication
52	CONMED5	Char	30	\$30.	\$30.	Concomitant Medication 5
53	CM5DOSE	Char	20	\$20.	\$20.	Con med 5 dose/route/sche
54	CM5INDIC	Char	1	\$X4687X.	\$1.	Con med 5 indication
55	CONMED6	Char	30	\$30.	\$30.	Concomitant Medication 6
56	CM6DOSE	Char	20	\$20.	\$20.	Con med 6 dose/route/sche
57	CM6INDIC	Char	1	\$X4687X.	\$1.	Con med 6 indication
58	CONMED7	Char	30	\$30.	\$30.	Concomitant Medication 7
59	CM7DOSE	Char	20	\$20.	\$20.	Con med 7 dose/route/sche
60	CM7INDIC	Char	1	\$X4687X.	\$1.	Con med 7 indication
61	CONMED8	Char	30	\$30.	\$30.	Concomitant Medication 8
62	CM8DOSE	Char	20	\$20.	\$20.	Con med 8 dose/route/sche
63	CM8INDIC	Char	1	\$X4687X.	\$1.	Con med 8 indication
64	CONMED9	Char	30	\$30.	\$30.	Concomitant Medication 9
65	CM9DOSE	Char	20	\$20.	\$20.	Con med 9 dose/route/sche
66	CM9INDIC	Char	1	\$X4687X.	\$1.	Con med 9 indication
67	CONMED10	Char	30	\$30.	\$30.	Concomitant medication 10
68	CM10DOSE	Char	20	\$20.	\$20.	Con med 10 dose/route/sch
69	CM10INDI	Char	1	\$X4687X.	\$1.	Con med 10 indication
70	CONMED11	Char	30	\$30.	\$30.	Concomitant medication 11
71	CM11DOSE	Char	20	\$20.	\$20.	Con med 11 dose/route/sch
72	CM11INDI	Char	1	\$X4687X.	\$1.	Con med 11 indication
73	CONMED12	Char	30	\$30.	\$30.	Concomitant medication 12
74	CM12DOSE	Char	20	\$20.	\$20.	Con med 12 dose/route/sch
75	CM12INDI	Char	1	\$X4687X.	\$1.	Con med 12 indication

Num	Variable	Type	Len	Format	Informat	Label
76	CONMED13	Char	30	\$30.	\$30.	Concomitant medication 13
77	CM13DOSE	Char	20	\$20.	\$20.	Con med 13 dose/route/sch
78	CM13INDI	Char	1	\$X4687X.	\$1.	Con med 13 indication
79	CONMED14	Char	30	\$30.	\$30.	Concomitant medication 14
80	CM14DOSE	Char	20	\$20.	\$20.	Con med 14 dose/route/sch
81	CM14INDI	Char	1	\$X4687X.	\$1.	Con med 14 indication
82	CONMED15	Char	30	\$30.	\$30.	Concomitant medication 15
83	CM15DOSE	Char	20	\$20.	\$20.	Con med 15 dose/route/sch
84	CM15INDI	Char	1	\$X4687X.	\$1.	Con med 15 indication
85	CONMED16	Char	30	\$30.	\$30.	Concomitant medication 16
86	CM16DOSE	Char	20	\$20.	\$20.	Con med 16 dose/route/sch
87	CM16INDI	Char	1	\$X4687X.	\$1.	Con med 16 indication
88	CONMED17	Char	30	\$30.	\$30.	Concomitant medication 17
89	CM17DOSE	Char	20	\$20.	\$20.	Con med 17 dose/route/sch
90	CM17INDI	Char	1	\$X4687X.	\$1.	Con med 17 indication
91	CONMED18	Char	30	\$30.	\$30.	Concomitant medication 18
92	CM18DOSE	Char	20	\$20.	\$20.	Con med 18 dose/route/sch
93	CM18INDI	Char	1	\$X4687X.	\$1.	Con med 18 indication
94	CONMED19	Char	30	\$30.	\$30.	Concomitant medication 19
95	CM19DOSE	Char	20	\$20.	\$20.	Con med 19 dose/route/sch
96	CM19INDI	Char	1	\$X4687X.	\$1.	Con med 19 indication
97	CONMED20	Char	30	\$30.	\$30.	Concomitant medication 20
98	CM20DOSE	Char	20	\$20.	\$20.	Con med 20 dose/route/sch
99	CM20INDI	Char	1	\$X4687X.	\$1.	Con med 20 indication
100	CONMED21	Char	30	\$30.	\$30.	Concomitant medication 21
101	CM21DOSE	Char	20	\$20.	\$20.	Con med 21 dose/route/sch
102	CM21INDI	Char	1	\$X4687X.	\$1.	Con med 21 indication
103	CONMED22	Char	30	\$30.	\$30.	Concomitant medication 22
104	CM22DOSE	Char	20	\$20.	\$20.	Con med 22 dose/route/sch
105	CM22INDI	Char	1	\$X4687X.	\$1.	Con med 22 indications
106	CONMED23	Char	30	\$30.	\$30.	Concomitant medication 23
107	CM23DOSE	Char	20	\$20.	\$20.	Con med 23 dose/route/sch
108	CM23INDI	Char	1	\$X4687X.	\$1.	Con med 23 indication
109	CONMED24	Char	30	\$30.	\$30.	Concomitant medication 24
110	CM24DOSE	Char	20	\$20.	\$20.	Con med 24 dose/route/sch
111	CM24INDI	Char	1	\$X4687X.	\$1.	Con med 24 indication
112	CONMED25	Char	30	\$30.	\$30.	Concomitant medication 25
113	CM25DOSE	Char	20	\$20.	\$20.	Con med 25 dose/route/sch
114	CM25INDI	Char	1	\$X4687X.	\$1.	Con med 25 indication

Num	Variable	Type	Len	Format	Informat	Label
115	LABTSTPF	Char	1	\$X1457X.	\$1.	Lab tests performed
116	ADLTST1	Char	20	\$20.	\$20.	Laboratory test 1
117	ADL1RES	Char	10	\$10.	\$10.	Lab test 1 result
118	ADL1NORG	Char	15	\$15.	\$15.	Lab test 1 normal range
119	ADL1PRVL	Char	10	\$10.	\$10.	Lab test 1 previous value
120	ADLTST2	Char	20	\$20.	\$20.	Laboratory test 2
121	ADL2RES	Char	10	\$10.	\$10.	Lab test 2 result
122	ADL2NORG	Char	15	\$15.	\$15.	Lab test 2 normal range
123	ADL2PRVL	Char	10	\$10.	\$10.	Lab test 2 previous value
124	ADLTST3	Char	20	\$20.	\$20.	Laboratory test 3
125	ADL3RES	Char	10	\$10.	\$10.	Lab test 3 result
126	ADL3NORG	Char	15	\$15.	\$15.	Lab test 3 normal range
127	ADL3PRVL	Char	10	\$10.	\$10.	Lab test 3 previous value
128	ADLTST4	Char	20	\$20.	\$20.	Laboratory test 4
129	ADL4RES	Char	10	\$10.	\$10.	Lab test 4 result
130	ADL4NORG	Char	15	\$15.	\$15.	Lab test 4 normal range
131	ADL4PRVL	Char	10	\$10.	\$10.	Lab test 4 previous value
132	ADLTST5	Char	20	\$20.	\$20.	Laboratory test 5
133	ADL5RES	Char	10	\$10.	\$10.	Lab test 5 result
134	ADL5NORG	Char	15	\$15.	\$15.	Lab test 5 normal range
135	ADL5PRVL	Char	10	\$10.	\$10.	Lab test 5 previous value
136	ADLTST6	Char	20	\$20.	\$20.	Laboratory test 6
137	ADL6RES	Char	10	\$10.	\$10.	Lab test 6 result
138	ADL6NORG	Char	15	\$15.	\$15.	Lab test 6 normal range
139	ADL6PRVL	Char	10	\$10.	\$10.	Lab test 6 previous value
140	ADLTST7	Char	20	\$20.	\$20.	Laboratory test 7
141	ADL7RES	Char	10	\$10.	\$10.	Lab test 7 result
142	ADL7NORG	Char	15	\$15.	\$15.	Lab test 7 normal range
143	ADL7PRVL	Char	10	\$10.	\$10.	Lab test 7 previous value
144	ADLTST8	Char	20	\$20.	\$20.	Laboratory test 8
145	ADL8RES	Char	10	\$10.	\$10.	Lab test 8 result
146	ADL8NORG	Char	15	\$15.	\$15.	Lab test 8 normal range
147	ADL8PRVL	Char	10	\$10.	\$10.	Lab test 8 previous value
148	ADLTST9	Char	20	\$20.	\$20.	Laboratory test 9
149	ADL9RES	Char	10	\$10.	\$10.	Lab test 9 result
150	ADL9NORG	Char	15	\$15.	\$15.	Lab test 9 normal range
151	ADL9PRVL	Char	10	\$10.	\$10.	Lab test 9 previous value
152	ADLTST10	Char	20	\$20.	\$20.	Laboratory test 10
153	ADL10RES	Char	10	\$10.	\$10.	Lab test 10 result

Num	Variable	Type	Len	Format	Informat	Label
154	ADL10NRG	Char	15	\$15.	\$15.	Lab test 10 normal range
155	ADL10PVL	Char	10	\$10.	\$10.	Lab test 10 prev value
156	DXSTPF	Char	1	\$X1457X.	\$1.	Diagnostic tests perform
157	ADDTS1	Char	20	\$20.	\$20.	Diagnostic test 1
158	ADDTS2	Char	20	\$20.	\$20.	Diagnostic test 2
159	ADDTS3	Char	20	\$20.	\$20.	Diagnostic test 3
160	ADDTS4	Char	20	\$20.	\$20.	Diagnostic test 4
161	ADDTS5	Char	20	\$20.	\$20.	Diagnostic test 5
162	ADDTS6	Char	20	\$20.	\$20.	Diagnostic test 6
163	ADDTS7	Char	20	\$20.	\$20.	Diagnostic test 7
164	ADDTS8	Char	20	\$20.	\$20.	Diagnostic test 8
165	ADDTS9	Char	20	\$20.	\$20.	Diagnostic test 9
166	ADDTS10	Char	20	\$20.	\$20.	Diagnostic test 10
167	AEREVIEW	Char	1	\$X1457X.	\$1.	Adverse event reviewed
168	AMDETER	Char	1	\$X1457X.	\$1.	SAE Determined
169	AMDETERU	Char	1	\$X1457X.	\$1.	SAE Determined Unexpected
170	AMRELTXP	Char	2	\$X34971X.	\$2.	Related to Transplant
171	AMRELBOR	Char	2	\$X34971X.	\$2.	Related to Bortezomib
172	AMRELMNT	Char	2	\$X34971X.	\$2.	Related to Maintenance
173	AMEXPFDA	Char	1	\$X1457X.	\$1.	Standard Expedited
174	AMEXPDSM	Char	1	\$X1457X.	\$1.	Expedite Reporting DSMB
175	AMWITHDR	Char	1	\$X1457X.	\$1.	Subject Withdrawn
176	AMREVDNE	Char	1	\$X1457X.	\$1.	Review Complete
177	AMMMEVDS	Char	35	\$35.	\$35.	MM Event Description
178	CTCAEGRD	Char	1	\$X30900X.	\$1.	CTCAE Grade of Event
179	AVAWARDT_DAYS	Num	8			Site awareness date (recode: number of days after consent)
180	AVRESDT_DAYS	Num	8			Date of resolution (recode: number of days after consent)
181	SEISUBDT_DAYS	Num	8			Initial submit date (recode: number of days after consent)
182	SEASUBDT_DAYS	Num	8			Authorized submit date (recode: number of days after consent)
183	SP1STDT_DAYS	Num	8			Study product 1 start dte (recode: number of days after consent)
184	SP1SPDT_DAYS	Num	8			Study product 1 stop date (recode: number of days after consent)
185	SP2STDT_DAYS	Num	8			Study product 2 start dte (recode: number of days after consent)
186	SP2SPDT_DAYS	Num	8			Study product 2 stop date (recode: number of days after consent)
187	SP3STDT_DAYS	Num	8			Study product 3 start dte (recode: number of days after consent)
188	SP3SPDT_DAYS	Num	8			Study product 3 stop date (recode: number of days after consent)
189	SP4STDT_DAYS	Num	8			Study product 4 start dte (recode: number of days after consent)
190	SP4SPDT_DAYS	Num	8			Study product 4 stop date (recode: number of days after consent)
191	CM1STDT_DAYS	Num	8			Con med 1 start date (recode: number of days after consent)
192	CM1SPDT_DAYS	Num	8			Con med 1 stop date (recode: number of days after consent)

Num	Variable	Type	Len	Format	Informat	Label
193	CM2STDT_DAYS	Num	8			Con med 2 start date (recode: number of days after consent)
194	CM2SPDT_DAYS	Num	8			Con med 2 stop date (recode: number of days after consent)
195	CM3STDT_DAYS	Num	8			Con med 3 start date (recode: number of days after consent)
196	CM3SPDT_DAYS	Num	8			Con med 3 stop date (recode: number of days after consent)
197	CM4STDT_DAYS	Num	8			Con med 4 start date (recode: number of days after consent)
198	CM4SPDT_DAYS	Num	8			Con med 4 stop date (recode: number of days after consent)
199	CM5STDT_DAYS	Num	8			Con med 5 start date (recode: number of days after consent)
200	CM5SPDT_DAYS	Num	8			Con med 5 stop date (recode: number of days after consent)
201	CM6STDT_DAYS	Num	8			Con med 6 start date (recode: number of days after consent)
202	CM6SPDT_DAYS	Num	8			Con med 6 stop date (recode: number of days after consent)
203	CM7STDT_DAYS	Num	8			Con med 7 start date (recode: number of days after consent)
204	CM7SPDT_DAYS	Num	8			Con med 7 stop date (recode: number of days after consent)
205	CM8STDT_DAYS	Num	8			Con med 8 start date (recode: number of days after consent)
206	CM8SPDT_DAYS	Num	8			Con med 8 stop date (recode: number of days after consent)
207	CM9STDT_DAYS	Num	8			Con med 9 start date (recode: number of days after consent)
208	CM9SPDT_DAYS	Num	8			Con med 9 stop date (recode: number of days after consent)
209	CM10STDT_DAYS	Num	8			Con med 10 start date (recode: number of days after consent)
210	CM10SPDT_DAYS	Num	8			Con med 10 stop date (recode: number of days after consent)
211	CM11STDT_DAYS	Num	8			Con med 11 start date (recode: number of days after consent)
212	CM11SPDT_DAYS	Num	8			Con med 11 stop date (recode: number of days after consent)
213	CM12STDT_DAYS	Num	8			Con med 12 start date (recode: number of days after consent)
214	CM12SPDT_DAYS	Num	8			Con med 12 stop date (recode: number of days after consent)
215	CM13STDT_DAYS	Num	8			Con med 13 start date (recode: number of days after consent)
216	CM13SPDT_DAYS	Num	8			Con med 13 stop date (recode: number of days after consent)
217	CM14STDT_DAYS	Num	8			Con med 14 start date (recode: number of days after consent)
218	CM14SPDT_DAYS	Num	8			Con med 14 stop date (recode: number of days after consent)
219	CM15STDT_DAYS	Num	8			Con med 15 start date (recode: number of days after consent)
220	CM15SPDT_DAYS	Num	8			Con med 15 stop date (recode: number of days after consent)
221	CM16STDT_DAYS	Num	8			Con med 16 start date (recode: number of days after consent)
222	CM16SPDT_DAYS	Num	8			Con med 16 stop date (recode: number of days after consent)
223	CM17STDT_DAYS	Num	8			Con med 17 start date (recode: number of days after consent)
224	CM17SPDT_DAYS	Num	8			Con med 17 stop date (recode: number of days after consent)
225	CM18STDT_DAYS	Num	8			Con med 18 start date (recode: number of days after consent)
226	CM18SPDT_DAYS	Num	8			Con med 18 stop date (recode: number of days after consent)
227	CM19STDT_DAYS	Num	8			Con med 19 start date (recode: number of days after consent)
228	CM19SPDT_DAYS	Num	8			Con med 19 stop date (recode: number of days after consent)
229	CM20STDT_DAYS	Num	8			Con med 20 start date (recode: number of days after consent)
230	CM20SPDT_DAYS	Num	8			Con med 20 stop date (recode: number of days after consent)
231	CM21STDT_DAYS	Num	8			Con med 21 start date (recode: number of days after consent)

Num	Variable	Type	Len	Format	Informat	Label
232	CM21SPDT_DAYS	Num	8			Con med 21 stop date (recode: number of days after consent)
233	CM22STDT_DAYS	Num	8			Con med 22 start date (recode: number of days after consent)
234	CM22SPDT_DAYS	Num	8			Con med 22 stop date (recode: number of days after consent)
235	CM23STDT_DAYS	Num	8			Con med 23 start date (recode: number of days after consent)
236	CM23SPDT_DAYS	Num	8			Con med 23 stop date (recode: number of days after consent)
237	CM24STDT_DAYS	Num	8			Con med 24 start date (recode: number of days after consent)
238	CM24SPDT_DAYS	Num	8			Con med 24 stop date (recode: number of days after consent)
239	CM25STDT_DAYS	Num	8			Con med 25 start date (recode: number of days after consent)
240	CM25SPDT_DAYS	Num	8			Con med 25 stop date (recode: number of days after consent)
241	ADL1CD_DAYS	Num	8			Lab test 1 collection dt (recode: number of days after consent)
242	ADL1PCD_DAYS	Num	8			Lab test 1 prev coll date (recode: number of days after consent)
243	ADL2CD_DAYS	Num	8			Lab test 2 collection dt (recode: number of days after consent)
244	ADL2PCD_DAYS	Num	8			Lab test 2 prev coll date (recode: number of days after consent)
245	ADL3CD_DAYS	Num	8			Lab test 3 collection dt (recode: number of days after consent)
246	ADL3PCD_DAYS	Num	8			Lab test 3 prev coll date (recode: number of days after consent)
247	ADL4CD_DAYS	Num	8			Lab test 4 collection dt (recode: number of days after consent)
248	ADL4PCD_DAYS	Num	8			Lab test 4 prev coll date (recode: number of days after consent)
249	ADL5CD_DAYS	Num	8			Lab test 5 collection dt (recode: number of days after consent)
250	ADL5PCD_DAYS	Num	8			Lab test 5 prev coll date (recode: number of days after consent)
251	ADL6CD_DAYS	Num	8			Lab test 6 collection dte (recode: number of days after consent)
252	ADL6PCD_DAYS	Num	8			Lab test 6 prev coll date (recode: number of days after consent)
253	ADL7CD_DAYS	Num	8			Lab test 7 collection dte (recode: number of days after consent)
254	ADL7PCD_DAYS	Num	8			Lab test 7 prev coll date (recode: number of days after consent)
255	ADL8CD_DAYS	Num	8			Lab test 8 collection dte (recode: number of days after consent)
256	ADL8PCD_DAYS	Num	8			Lab test 8 prev coll date (recode: number of days after consent)
257	ADL9CD_DAYS	Num	8			Lab test 9 collection dte (recode: number of days after consent)
258	ADL9PCD_DAYS	Num	8			Lab test 9 prev coll date (recode: number of days after consent)
259	ADL10CD_DAYS	Num	8			Lab test 10 collection dt (recode: number of days after consent)
260	ADL10PCD_DAYS	Num	8			Lab test 10 prev coll dte (recode: number of days after consent)
261	AD1DTDAT_DAYS	Num	8			Date of diag test 1 (recode: number of days after consent)
262	AD2DTDAT_DAYS	Num	8			Date of diag test 2 (recode: number of days after consent)
263	AD3DTDAT_DAYS	Num	8			Date of diag test 3 (recode: number of days after consent)
264	AD4DTDAT_DAYS	Num	8			Date of diag test 4 (recode: number of days after consent)
265	AD5DTDAT_DAYS	Num	8			Date of diag test 5 (recode: number of days after consent)
266	AD6DTDAT_DAYS	Num	8			Date of diag test 6 (recode: number of days after consent)
267	AD7DTDAT_DAYS	Num	8			Date of diag test 7 (recode: number of days after consent)
268	AD8DTDAT_DAYS	Num	8			Date of diag test 8 (recode: number of days after consent)
269	AD9DTDAT_DAYS	Num	8			Date of diag test 9 (recode: number of days after consent)
270	AD10DTDT_DAYS	Num	8			Date of diag test 10 (recode: number of days after consent)

Num	Variable	Type	Len	Format	Informat	Label
271	ARFREVDT_DAYS	Num	8			Review form review date (recode: number of days after consent)
272	ADVDATE_DAYS	Num	8			Date of Onset (recode: number of days after consent)

Data Set Name: bss.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	PROTSEG	Char	1	\$1.	\$1.	Protocol Segment
4	BRTADVDS	Char	1	\$XBRTAVEVTX.	\$1.	Event Description
5	BSSOTADV	Char	50	\$50.	\$50.	Other Adverse Event Descr
6	BSSRLBRT	Char	1	\$X4681X.	\$1.	Bortezomib Relationship
7	BSSEVASS	Char	1	\$X4685X.	\$1.	Event Associated With
8	BSSEVRSL	Char	1	\$X1457X.	\$1.	Event Resolved
9	ADVDATE_DAYS	Num	8			Date of Onset (recode: number of days after consent)
10	BSSRESDT_DAYS	Num	8			Resolution Date (recode: number of days after consent)

Data Set Name: cr7.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	PROTSEG	Char	1	\$1.	\$1.	Protocol Segment
4	VISNO	Char	4	\$4.	\$4.	Visit Number
5	CR7BSA	Num	8	6.2	6.2	Body Surface Area
6	CR7WTTYP	Char	1	\$X31928X.	\$1.	Body Weight Type
7	CR7PTWT	Num	8	7.1	7.1	Patient Weight
8	CR7F1DOS	Num	8	4.	4.	Fludarabine Dose 1
9	CR7F2DOS	Num	8	4.	4.	Fludarabine Dose 2
10	CR7F3DOS	Num	8	4.	4.	Fludarabine Dose 3
11	CR7F4DOS	Num	8	4.	4.	Fludarabine Dose 4
12	CR7M1DOS	Num	8	4.	4.	Melphalan Dose 1
13	CR7M2DOS	Num	8	4.	4.	Melphalan Dose 2
14	CR7B1DOS	Num	8	6.2	6.2	Bortezomib Dose 1
15	CR7B2DOS	Num	8	6.2	6.2	Bortezomib Dose 2
16	CR7B3DOS	Num	8	6.2	6.2	Bortezomib Dose 3
17	CR7B4DOS	Num	8	6.2	6.2	Bortezomib Dose 4
18	CR7BSADT_DAYS	Num	8			Body Surface Area Date (recode: number of days after consent)
19	CR7PTWTD_DAYS	Num	8			Patient Weight Date (recode: number of days after consent)
20	CR7F1DT_DAYS	Num	8			Fludarabine Dose 1 Date (recode: number of days after consent)
21	CR7F2DT_DAYS	Num	8			Fludarabine Dose 2 Date (recode: number of days after consent)
22	CR7F3DT_DAYS	Num	8			Fludarabine Dose 3 Date (recode: number of days after consent)
23	CR7F4DT_DAYS	Num	8			Fludarabine Dose 4 Date (recode: number of days after consent)
24	CR7M1DT_DAYS	Num	8			Melphalan Dose 1 Date (recode: number of days after consent)
25	CR7M2DT_DAYS	Num	8			Melphalan Dose 2 Date (recode: number of days after consent)
26	CR7B1DT_DAYS	Num	8			Bortezomib Dose 1 Date (recode: number of days after consent)
27	CR7B2DT_DAYS	Num	8			Bortezomib Dose 2 Date (recode: number of days after consent)
28	CR7B3DT_DAYS	Num	8			Bortezomib Dose 3 Date (recode: number of days after consent)
29	CR7B4DT_DAYS	Num	8			Bortezomib Dose 4 Date (recode: number of days after consent)

Data Set Name: dem.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	GENDER	Char	1	\$X1399X.	\$1.	Gender
4	ETHNIC	Char	3	\$X2518X.	\$3.	Ethnicity
5	RACEG	Num	8	RACEGF.		Race (grouped: 1=White, 2=Black/Other, 9=Unknown/missing)

Data Set Name: dth.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	AUTPERF	Char	1	\$X1457X.	\$1.	Autopsy performed
4	CZDTHPRM	Char	4	\$X1488X.	\$4.	Primary Cause of Death
5	DTHSPEC1	Char	50	\$50.	\$50.	Cause specify 1
6	SCNDCZ1	Char	4	\$X1488X.	\$4.	Secondary cause death
7	DTHSPEC2	Char	50	\$50.	\$50.	Cause specify 2
8	SCNDCZ2	Char	4	\$X1488X.	\$4.	Secondary cause death
9	DTHDT_DAYS	Num	8			Date of Death (recode: number of days after consent)

Data Set Name: ec1302a.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	AMADISC	Char	1	\$X35019X.	\$1.	Disease Classification
4	AMA13DEL	Char	1	\$X1457X.	\$1.	Deletion of Chromo 13
5	AMAHYPOD	Char	1	\$X1457X.	\$1.	Presence of Hypodiploidy
6	AMA1ABNO	Char	1	\$X1457X.	\$1.	Abnormality in Chromo 1
7	AMA17DEL	Char	1	\$X1457X.	\$1.	Deletion of 17p
8	AMAGEP	Char	1	\$X1457X.	\$1.	High Risk by GEP
9	AMAPRPRG	Char	1	\$X34963X.	\$1.	Number of Progressions
10	AMAPRGVG	Char	1	\$X1457X.	\$1.	VGPR From Progression
11	AMAPR	Char	1	\$X1457X.	\$1.	PR or Better
12	AMAVGPR	Char	1	\$X1457X.	\$1.	VGPR or Better
13	AMAPRAUT	Char	1	\$X1457X.	\$1.	Prior Auto Transplant
14	AMASYSTP	Char	1	\$X1457X.	\$1.	Systemic Therapy
15	AMALVEF	Num	8	4.	4.	LVEF Value
16	AMAESTCR	Num	8	4.	4.	Estimated Creatinine
17	AMADLCO	Num	8	4.	4.	DLCO Value
18	AMAFEV	Num	8	4.	4.	FEV1 Value
19	AMAGILD	Char	1	\$X1457X.	\$1.	Gilbert's Disease
20	AMABILI	Num	8	6.1	6.1	Bilirubin Value
21	AMABILUL	Num	8	6.1	6.1	Bilirubin ULN
22	AMAALT	Num	8	4.	4.	ALT Value
23	AMAALTUL	Num	8	4.	4.	ALT ULN
24	AMAAST	Num	8	4.	4.	AST Value
25	AMAASTUL	Num	8	4.	4.	AST ULN
26	AMAFCBP	Char	1	\$X1635X.	\$1.	FCBP
27	AMAAGBCF	Char	1	\$X1457X.	\$1.	Agree BC Female
28	AMAAGBCM	Char	1	\$X1457X.	\$1.	Agree BC Male
29	AMAPRORQ	Char	1	\$X1457X.	\$1.	Comply Prot Reqs
30	AMAKPS	Char	2	\$X12323X.	\$2.	Karnofsky Score
31	AMAALLO	Char	1	\$X1457X.	\$1.	Prior Allo HCT
32	AMANONSE	Char	1	\$X1457X.	\$1.	Non-Secretory MM
33	AMAPLDLI	Char	1	\$X1457X.	\$1.	Planned DLI
34	AMACNSIN	Char	1	\$X1457X.	\$1.	CNS Involvement
35	AMAINF	Char	1	\$X1457X.	\$1.	Active Infection
36	AMAFLUCO	Char	1	\$X1457X.	\$1.	Fluid Collection

Num	Variable	Type	Len	Format	Informat	Label
37	AMAHIV	Char	1	\$X1457X.	\$1.	HIV Positive
38	AMAAMYLD	Char	1	\$X1457X.	\$1.	Amyloidosis
39	AMAHEPBC	Char	1	\$X1457X.	\$1.	Active Hep BC
40	AMASENBO	Char	1	\$X1457X.	\$1.	Bortez Sensitive
41	AMAGIDIS	Char	1	\$X1457X.	\$1.	GI Disease
42	AMAKNOAL	Char	1	\$X1457X.	\$1.	Known Allergy
43	AMAGR2PN	Char	1	\$X1457X.	\$1.	Gr2 Peripheral Neuropathy
44	AMAMYOCA	Char	1	\$X1457X.	\$1.	Myocardial Infarction
45	AMAPREG	Char	1	\$X1635X.	\$1.	Lactating or Pregnant
46	AMAPRMAL	Char	1	\$X2439X.	\$1.	HX of Prior Malignancy
47	AMA5YRS	Char	1	\$X1457X.	\$1.	Treated More Than 5yrs
48	AMAPRTOX	Char	1	\$X1457X.	\$1.	Prior Chemo Toxicity
49	AMACHEMO	Char	1	\$X1457X.	\$1.	Recovered Prior Chemo
50	AMAPSYIL	Char	1	\$X1457X.	\$1.	Psychiatric Illness
51	AMAINVAG	Char	1	\$X1457X.	\$1.	Other Invest Agent
52	AMARADIO	Char	1	\$X1457X.	\$1.	Radiation
53	AMADTYPE	Char	1	\$X30306X.	\$1.	Donor Type
54	AMATWIN	Char	1	\$X1457X.	\$1.	Donor Identical Twin
55	AMADPRG	Char	1	\$X1635X.	\$1.	Donor Pregnant
56	AMADHIVP	Char	1	\$X1457X.	\$1.	Donor HIV Positive
57	AMADINV	Char	1	\$X2439X.	\$1.	Donor Exp Therapy
58	AMADPBSC	Char	1	\$X1457X.	\$1.	Donor Willing PBSC
59	AMAOPTBL	Char	1	\$X1457X.	\$1.	Optional Blood Samples
60	AMAOPTMR	Char	1	\$X1457X.	\$1.	Optional Bone Marrow
61	AMAPRGDT_DAYS	Num	8			Date of Progression (recode: number of days after consent)
62	AMATXPDT_DAYS	Num	8			Auto Txp Date (recode: number of days after consent)
63	AMASYSDT_DAYS	Num	8			Systemic Therapy Date (recode: number of days after consent)
64	AMALVDT_DAYS	Num	8			LVEF Date (recode: number of days after consent)
65	AMACRDT_DAYS	Num	8			Creatinine Clearance Date (recode: number of days after consent)
66	AMADLCDT_DAYS	Num	8			DLCO Date (recode: number of days after consent)
67	AMAFEVDT_DAYS	Num	8			FEV1 Date (recode: number of days after consent)
68	AMABILDT_DAYS	Num	8			Bilirubin Date (recode: number of days after consent)
69	AMAALTDT_DAYS	Num	8			ALT Date (recode: number of days after consent)
70	AMAASDT_DAYS	Num	8			AST Date (recode: number of days after consent)
71	AMABLDT_DAYS	Num	8			Blood Sample Consent Date (recode: number of days after consent)
72	AMAMRDT_DAYS	Num	8			Bone Marrow Consent Date (recode: number of days after consent)

Data Set Name: ec1302b.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	AMBPRPRG	Char	1	\$X34963X.	\$1.	Progression Before Seg A
4	AMBGILBD	Char	1	\$X1457X.	\$1.	Gilbert Disease
5	AMBBILI	Num	8	6.1	6.1	Bilirubin Value
6	AMBBILUL	Num	8	6.1	6.1	Bilirubin ULN
7	AMBALT	Num	8	4.	4.	ALT Value
8	AMBALTUL	Num	8	4.	4.	ALT ULN
9	AMBAST	Num	8	4.	4.	AST Value
10	AMBASTUL	Num	8	4.	4.	AST ULN
11	AMBANC	Num	8	6.	6.	ANC Value
12	AMBPLATE	Num	8	7.	7.	Platelet Count
13	AMBV2GVH	Char	1	\$X1457X.	\$1.	Grade 2 Visceral aGVHD
14	AMBG3GVH	Char	1	\$X1457X.	\$1.	Grade 3 Acute GVHD
15	AMBPRG	Char	1	\$X1457X.	\$1.	Progression Post Entry
16	AMBPN	Char	1	\$X1457X.	\$1.	Peripheral Neuropathy
17	AMBPNGRD	Char	1	\$X1457X.	\$1.	Periph Neuropathy Grade
18	AMBTACRO	Char	1	\$X1457X.	\$1.	Tolerating Tacrolimus
19	AMBFCBP	Char	1	\$X1635X.	\$1.	FCBP Patient
20	AMBNPREG	Char	1	\$X1457X.	\$1.	Negative Pregnancy Test
21	AMBLACT	Char	1	\$X1457X.	\$1.	FCBP Lactating
22	AMBNHTOX	Char	1	\$X1457X.	\$1.	Non Hematologic Toxicity
23	AMBTXRES	Char	1	\$X1457X.	\$1.	Non Hem Tox Resolved
24	AMBRDTHP	Char	1	\$X21301X.	\$1.	Radiotherapy Received
25	AMBCNS	Char	1	\$X1457X.	\$1.	CNS Involvement
26	AMBINFACT	Char	1	\$X1457X.	\$1.	Serious Infection
27	AMBSYTH	Char	1	\$X1457X.	\$1.	Systemic Therapy Received
28	AMBORLMD	Char	1	\$X1457X.	\$1.	Swallow Oral Medication
29	AMBCMPY	Char	1	\$X1457X.	\$1.	Drug Admin Compliance
30	AMBGASTR	Char	1	\$X1457X.	\$1.	GI Procedure Interference
31	AMBMNTDT_DAYS	Num	8			Proposed Maintenance Date (recode: number of days after consent)
32	AMBBILDT_DAYS	Num	8			Bilirubin Date (recode: number of days after consent)
33	AMBALTDT_DAYS	Num	8			ALT Date (recode: number of days after consent)
34	AMBASTDT_DAYS	Num	8			AST Date (recode: number of days after consent)
35	AMBANCDT_DAYS	Num	8			ANC Date (recode: number of days after consent)
36	AMBPLTDT_DAYS	Num	8			Platelet Date (recode: number of days after consent)

Data Set Name: f18.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	PROTSEG	Char	1	\$1.	\$1.	Protocol Segment
4	VISNO	Char	4	\$4.	\$4.	Visit Number
5	F18PTDTH	Char	1	\$X15247X.	\$1.	Has Patient Died
6	F18PRGRS	Char	1	\$X15248X.	\$1.	Has Disease Progressed
7	F18THRPY	Char	1	\$X15249X.	\$1.	Any Non-Protocol Therapy
8	F18REAS	Char	80	\$80.	\$80.	Other Therapy Reason
9	F18TYDRG	Char	2	\$X15250X.	\$2.	Therapy Drug Initiated
10	F18TPYSP	Char	80	\$80.	\$80.	Other Therapy Specify
11	F18INFEC	Char	1	\$X15251X.	\$1.	Any New Infections
12	F18HOSP	Char	1	\$X15252X.	\$1.	Patient Hospitalized
13	F18TRANS	Char	1	\$X15253X.	\$1.	Non-Protocol Transplant
14	F18GRAFT	Char	1	\$X15254X.	\$1.	Secondary Graft Failure
15	F18UAE	Char	1	\$X15255X.	\$1.	Any Unexpected AEs
16	F18CNCR	Char	1	\$X15256X.	\$1.	Second Cancer Diagnosis
17	F18CNTDT_DAYS	Num	8			Date of Last Contact (recode: number of days after consent)
18	F18DTHDT_DAYS	Num	8			Date of Patient Death (recode: number of days after consent)
19	F18PRGDT_DAYS	Num	8			Date of Progression (recode: number of days after consent)
20	F18TPYDT_DAYS	Num	8			Therapy Start Date (recode: number of days after consent)
21	F18INFDT_DAYS	Num	8			New Infection Date (recode: number of days after consent)
22	F18HSPDT_DAYS	Num	8			Hospitalization Date (recode: number of days after consent)
23	F18TRNDT_DAYS	Num	8			Non-Prot Transplant Date (recode: number of days after consent)
24	F18GRFDT_DAYS	Num	8			Graft Failure Date (recode: number of days after consent)
25	F18UAEDT_DAYS	Num	8			Unexpected AE Date (recode: number of days after consent)

Data Set Name: fct.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	PROTSEG	Char	1	\$1.	\$1.	Protocol Segment
4	VISNO	Char	4	\$4.	\$4.	Visit Number
5	LCKENRG	Char	1	\$X3849X.	\$1.	Lack of energy
6	NAUSEA	Char	1	\$X3849X.	\$1.	I have nausea
7	FMLYNEED	Char	1	\$X3849X.	\$1.	Family needs
8	PAIN	Char	1	\$X3849X.	\$1.	I have pain
9	SIDEFFCT	Char	1	\$X3849X.	\$1.	Side effects
10	FEELILL	Char	1	\$X3849X.	\$1.	I feel ill
11	TIMINBED	Char	1	\$X3849X.	\$1.	Time in bed
12	CLSFRNDS	Char	1	\$X3849X.	\$1.	Feel close to friends
13	FAMSPRT	Char	1	\$X3849X.	\$1.	Emotional support(family)
14	FRNDSPRT	Char	1	\$X3849X.	\$1.	Support (friends)
15	ACPTILNS	Char	1	\$X3849X.	\$1.	Accept illness (Family)
16	SFAMCOMN	Char	1	\$X3849X.	\$1.	Satisfied Family Communic
17	PRTNRSPT	Char	1	\$X3849X.	\$1.	Partner support
18	CHECKBOX	Char	1	\$X1457X.	\$1.	Checkbox option for sex
19	SEXLIFE	Char	1	\$X3849X.	\$1.	Satisfaction c sex life
20	FEELSAD	Char	1	\$X3849X.	\$1.	I feel sad
21	COPING	Char	1	\$X3849X.	\$1.	How I'm coping
22	LOSEHOPE	Char	1	\$X3849X.	\$1.	I'm losing hope in fight
23	NERVOUS	Char	1	\$X3849X.	\$1.	9b. Very nervous person
24	WORRYDIE	Char	1	\$X3849X.	\$1.	I worry about dying
25	WORSEN	Char	1	\$X3849X.	\$1.	Worry of worsening
26	WORK	Char	1	\$X3849X.	\$1.	I am able to work
27	FULFILL	Char	1	\$X3849X.	\$1.	My work is fulfilling
28	ENJYLIFE	Char	1	\$X3849X.	\$1.	I am able to enjoy life
29	ACCEPTED	Char	1	\$X3849X.	\$1.	I've accepted my illness
30	SLEEPWEL	Char	1	\$X3849X.	\$1.	I am sleeping well
31	FUN	Char	1	\$X3849X.	\$1.	I am enjoying things
32	QOL	Char	1	\$X3849X.	\$1.	Content c Quality of life
33	JOB	Char	1	\$X3849X.	\$1.	Concern with keeping job
34	DISTANT	Char	1	\$X3849X.	\$1.	Distant from others
35	TRNSPWRY	Char	1	\$X3849X.	\$1.	Worry transplant wont wrk
36	TXEFFX	Char	1	\$X3849X.	\$1.	Treatment effects

Num	Variable	Type	Len	Format	Informat	Label
37	APPETITE	Char	1	\$X3849X.	\$1.	I have a good appetite
38	BDYAPRNC	Char	1	\$X3849X.	\$1.	Body appearance
39	GETARND	Char	1	\$X3849X.	\$1.	I get around
40	GETTIRED	Char	1	\$X3849X.	\$1.	I get tired easily
41	SEXINTRS	Char	1	\$X3849X.	\$1.	Interest in sex
42	FERTILTY	Char	1	\$X3849X.	\$1.	Concern about fertility
43	NURSE	Char	1	\$X3849X.	\$1.	Confidence in nurses
44	BMTREGRT	Char	1	\$X3849X.	\$1.	Regret having BMT
45	MEMORY	Char	1	\$X3849X.	\$1.	I can remember things
46	CNCTRATE	Char	1	\$X3849X.	\$1.	I'm able to concentrate
47	COLDS	Char	1	\$X3849X.	\$1.	I have frequent colds/inf
48	EYESIGHT	Char	1	\$X3849X.	\$1.	My eyesight is blurry
49	GUSTATOR	Char	1	\$X3849X.	\$1.	Change in way food tastes
50	TREMORS	Char	1	\$X3849X.	\$1.	I have tremors
51	SHRTBRTH	Char	1	\$X3849X.	\$1.	I've been short of breath
52	SKINPROB	Char	1	\$X3849X.	\$1.	Skin problems (rash,itch)
53	BOWELS	Char	1	\$X3849X.	\$1.	Trouble with bowels
54	HARDSHIP	Char	1	\$X3849X.	\$1.	Illness hardship c family
55	COSTOFTX	Char	1	\$X3849X.	\$1.	Cost of treatment
56	FACTDATE_DAYS	Num	8			Date FACT Performed (recode: number of days after consent)

Data Set Name: fgy.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	PROTSEG	Char	1	\$1.	\$1.	Protocol Segment
4	VISNO	Char	4	\$4.	\$4.	Visit Number
5	FGGRAGVH	Char	1	\$X2235X.	\$1.	Max Grade of aGVHD
6	FGAGVDVL	Char	1	\$X1457X.	\$1.	aGVHD Develop This Assess
7	FGASKNAB	Char	1	\$X1825X.	\$1.	Acute Skin Abnormalities
8	FGAUGIAB	Char	1	\$X1830X.	\$1.	Acute Upper GI Abnormal
9	FGALGIAB	Char	1	\$X6636X.	\$1.	Acute Lower GI Abnormal
10	FGALVRAB	Char	1	\$X1829X.	\$1.	Acute Liver Abnormalities
11	FGPROPIM	Char	1	\$X11444X.	\$1.	Immuno for Prophylaxis
12	FGPRATG	Char	1	\$X1457X.	\$1.	ATG Prophylaxis
13	FGPRBORT	Char	1	\$X1457X.	\$1.	Bortizomib Prophylaxis
14	FGPRCAMP	Char	1	\$X1457X.	\$1.	Campath Prophylaxis
15	FGPRCYPH	Char	1	\$X1457X.	\$1.	Cyclophosphamide Prophyl
16	FGPRCYCL	Char	1	\$X1457X.	\$1.	Cyclosporine Prophylaxis
17	FGPRMMF	Char	1	\$X1457X.	\$1.	MMF Prophylaxis
18	FGPRMRVR	Char	1	\$X1457X.	\$1.	Maraviroc Prophylaxis
19	FGPRMTRX	Char	1	\$X1457X.	\$1.	Methotrexate Prophylaxis
20	FGPRPRED	Char	1	\$X1457X.	\$1.	Prednisone Prophylaxis
21	FGPRSIR	Char	1	\$X1457X.	\$1.	Sirolimus Prophylaxis
22	FGPRTAC	Char	1	\$X1457X.	\$1.	Tacrolimus Prophylaxis
23	FGPROTHR	Char	1	\$X1457X.	\$1.	Other Prophylaxis
24	FGPROTSP	Char	50	\$50.	\$50.	Specify Other Prophylaxis
25	FGSVCGVH	Char	1	\$X26575X.	\$1.	Max Severity of cGVHD
26	FGCGVDVL	Char	1	\$X1457X.	\$1.	cGVHD Develop This Assess
27	FGDGKNLN	Char	2	\$X12323X.	\$2.	Karnofsky/Lansky Diagnos
28	FGDGPLT	Num	8	7.	7.	Platelet Count Diagnosis
29	FGDGALKP	Num	8	5.	5.	Alkaline Phosph Diagnosis
30	FGDGWGT	Num	8	7.1	7.1	Weight at Diagnosis
31	FGDGBILI	Num	8	6.1	6.1	Total Bilirubin Diagnosis
32	FGRSDIAG	Char	1	\$X1457X.	\$1.	Rash at Diagnosis
33	FGDRDIAG	Char	1	\$X1457X.	\$1.	Diarrhea at Diagnosis
34	FGSKNINV	Char	1	\$X26585X.	\$1.	Extent Skin Involvement
35	FGRSLICH	Char	1	\$X1457X.	\$1.	Lichenoid Rash
36	FGRSMACU	Char	1	\$X1457X.	\$1.	Maculopapular Rash

Num	Variable	Type	Len	Format	Informat	Label
37	FGRSSCLR	Char	1	\$X1457X.	\$1.	Sclerodermatous Rash
38	FGRSOTHR	Char	1	\$X1457X.	\$1.	Other Rash
39	FGRSOTSP	Char	30	\$30.	\$30.	Other Rash Specify
40	FGXEROPH	Char	1	\$X4540X.	\$1.	Xerophthalmia
41	FGMUCOS	Char	1	\$X4542X.	\$1.	Mucositis (functional)
42	FGBRNCH	Char	1	\$X5284X.	\$1.	Bronchiolitis Obliterans
43	FGFEV1VL	Num	8	4.	4.	FEV1 Value
44	FGFVCVL	Num	8	4.	4.	FVC Value
45	FGDLCOVL	Num	8	4.	4.	DLCO Value
46	FGESOPH	Char	1	\$X26577X.	\$1.	Esophagus
47	FGNAUSVM	Char	1	\$X1830X.	\$1.	Nausea and Vomiting
48	FGDIARH	Char	1	\$X5654X.	\$1.	Diarrhea
49	FGBILI	Num	8	6.1	6.1	Bilirubin Value
50	FGALT	Num	8	5.	5.	ALT Value
51	FGAST	Num	8	5.	5.	AST Value
52	FGALKPH	Num	8	5.	5.	Alkaline Phosph Value
53	FGVAGNIT	Char	1	\$X4553X.	\$1.	Non-infective Vaginitis
54	FGCONTRC	Char	1	\$X26578X.	\$1.	Contractures
55	FGMYOSIT	Char	1	\$X1457X.	\$1.	Myositis
56	FGEOSINP	Char	1	\$X1457X.	\$1.	Eosinophilia
57	FGSEROS	Char	1	\$X1457X.	\$1.	Serositis
58	FGFASCIT	Char	1	\$X1457X.	\$1.	Fascitis
59	FGOTORGN	Char	1	\$X1457X.	\$1.	Other Organ Involve
60	FGOTORSP	Char	50	\$50.	\$50.	Specify Other Organ
61	FGBIOPSY	Char	1	\$X1457X.	\$1.	Biopsy for GVHD
62	FGBIO1TY	Char	1	\$X5285X.	\$1.	Biopsy Type 1
63	FGBIO1RS	Char	1	\$X26579X.	\$1.	Biopsy Result 1
64	FGBIO2TY	Char	1	\$X5285X.	\$1.	Biopsy Type 2
65	FGBIO2RS	Char	1	\$X26579X.	\$1.	Biopsy Result 2
66	FGBIO3TY	Char	1	\$X5285X.	\$1.	Biopsy Type 3
67	FGBIO3RS	Char	1	\$X26579X.	\$1.	Biopsy Result 3
68	FGCHRTRT	Char	1	\$X26581X.	\$1.	Treatment of Chronic GVHD
69	FGTHATG	Char	1	\$X1457X.	\$1.	ALS, ALG, ATS, ATG Therap
70	FGTHAZAT	Char	1	\$X1457X.	\$1.	Azathioprine Therapy
71	FGTHCYCL	Char	1	\$X1457X.	\$1.	Cyclosporine Therapy
72	FGTHSYCO	Char	1	\$X1457X.	\$1.	Systemic Cortico Therapy
73	FGTHTPCO	Char	1	\$X1457X.	\$1.	Topical Cortico Therapy
74	FGTHTHAL	Char	1	\$X1457X.	\$1.	Thalidomide Therapy
75	FGTHTAC	Char	1	\$X1457X.	\$1.	Tacrolimus-FK506 Therapy

Num	Variable	Type	Len	Format	Informat	Label
76	FGTHMMF	Char	1	\$X1457X.	\$1.	MMF Therapy
77	FGTHPUVA	Char	1	\$X1457X.	\$1.	PUVA Therapy
78	FGTHECP	Char	1	\$X1457X.	\$1.	ECP Therapy
79	FGTHSIR	Char	1	\$X1457X.	\$1.	Sirolimus Therapy
80	FGTHETR	Char	1	\$X1457X.	\$1.	Etretinate Therapy
81	FGTHLAMP	Char	1	\$X1457X.	\$1.	Lamprene Therapy
82	FGTHETAN	Char	1	\$X1457X.	\$1.	Etanercept Therapy
83	FGTHZENA	Char	1	\$X1457X.	\$1.	Zenapax Therapy
84	FGTHCHPH	Char	1	\$X1457X.	\$1.	Chloroquine Phosph Therap
85	FGTHMAB	Char	1	\$X1457X.	\$1.	In Vivo MAB Therapy
86	FGTHIMM	Char	1	\$X1457X.	\$1.	In Vivio Immuno Therapy
87	FGTHOTHR	Char	1	\$X1457X.	\$1.	Other Therapy
88	FGTHOTSP	Char	50	\$50.	\$50.	Specify Other Agent
89	DTPRVAST_DAYS	Num	8			Start Date of Assessment (recode: number of days after consent)
90	DTASSESS_DAYS	Num	8			End Date of Assessment (recode: number of days after consent)
91	FGAGDGDТ_DAYS	Num	8			Date aGVHD Diagnosed (recode: number of days after consent)
92	FGPRCDT_DAYS	Num	8			GVHD Prophyl Discont Date (recode: number of days after consent)
93	FGCGDGDТ_DAYS	Num	8			Date cGVHD Diagnosed (recode: number of days after consent)
94	FGFEV1DT_DAYS	Num	8			Date FEV1 obtained (recode: number of days after consent)
95	FGBILIDT_DAYS	Num	8			Date Bilirubin Obtained (recode: number of days after consent)
96	FGALTDТ_DAYS	Num	8			Date ALT Obtained (recode: number of days after consent)
97	FGASTDT_DAYS	Num	8			Date AST Obtained (recode: number of days after consent)
98	FGAKPHDT_DAYS	Num	8			Date Alkaline Phos Obtain (recode: number of days after consent)
99	FGBIO1DT_DAYS	Num	8			Biopsy Date 1 (recode: number of days after consent)
100	FGBIO2DT_DAYS	Num	8			Biopsy Date 2 (recode: number of days after consent)
101	FGBIO3DT_DAYS	Num	8			Biopsy Date 3 (recode: number of days after consent)
102	FGCTRTDT_DAYS	Num	8			Date Chronic Treat Start (recode: number of days after consent)

Data Set Name: gvh.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	PROTSEG	Char	1	\$1.	\$1.	Protocol Segment
4	VISNO	Char	4	\$4.	\$4.	Visit Number
5	IMMUNORC	Char	1	\$X54237X.	\$1.	Immunosuppressant Recvd
6	TROUGHLEV	Num	8	8.1	8.1	Most Recent Immun Level
7	GVHSKINA	Char	1	\$X1825X.	\$1.	Skin Abnormalities
8	SETGVHD	Char	1	\$X1457X.	\$1.	Skin Etiology GVHD
9	SETDRGRX	Char	1	\$X1457X.	\$1.	Skin Etiology Drug Reacti
10	SETCRTOX	Char	1	\$X1457X.	\$1.	Skin Etiology Cnd Reg Tox
11	SETINFCT	Char	1	\$X1457X.	\$1.	Skin Etiology Infection
12	SETOTHER	Char	1	\$X1457X.	\$1.	Skin Etiology Other
13	GVHSKNSP	Char	50	\$50.	\$50.	Skin Etiology Specify
14	GVHSKINB	Char	1	\$X1822X.	\$1.	Skin Biopsy Results
15	GVHUPGIA	Char	1	\$X1830X.	\$1.	Upper GI Abnormalities
16	UGIETGVH	Char	1	\$X1457X.	\$1.	UGI Etiology GVHD
17	UGIETDRG	Char	1	\$X1457X.	\$1.	UGI Etiology Drug Rxn
18	UGIETCON	Char	1	\$X1457X.	\$1.	UGI Etiology Cond Reg Tox
19	UGIETTPN	Char	1	\$X1457X.	\$1.	UGI Etiology TPN
20	UGIETINF	Char	1	\$X1457X.	\$1.	UGI Etiology Infection
21	UGIETOTH	Char	1	\$X1457X.	\$1.	UGI Etiology Other
22	UGIETSPC	Char	50	\$50.	\$50.	UGI Etiology Specify
23	UGIBIORS	Char	1	\$X1822X.	\$1.	UGI Biopsy Results
24	GVHINTA	Char	1	\$X6636X.	\$1.	Lower GI Abnormalities
25	LGIETGVH	Char	1	\$X1457X.	\$1.	LGI Etiology GVHD
26	LGIETDRG	Char	1	\$X1457X.	\$1.	LGI Etiology Drug Rxn
27	LGIETCON	Char	1	\$X1457X.	\$1.	LGI Etiology Cond Reg Tox
28	LGIETTPN	Char	1	\$X1457X.	\$1.	LGI Etiology TPN
29	LGIETINF	Char	1	\$X1457X.	\$1.	LGI Etiology Infection
30	LGIETOTH	Char	1	\$X1457X.	\$1.	LGI Etiology Other
31	LGIETSPC	Char	50	\$50.	\$50.	LGI Etiology Specify
32	LGIBIORS	Char	1	\$X1822X.	\$1.	LGI Biopsy Results
33	GVHLIVRA	Char	1	\$X1829X.	\$1.	Liver Abnormalities
34	LIVETGVH	Char	1	\$X1457X.	\$1.	Liver Etiology GVHD
35	LIVETDRG	Char	1	\$X1457X.	\$1.	Liver Etiology Drug Rxn
36	LIVETCND	Char	1	\$X1457X.	\$1.	Liver Etiology Cnd Reg Tx

Num	Variable	Type	Len	Format	Informat	Label
37	LIVETTPN	Char	1	\$X1457X.	\$1.	Liver Etiology TPN
38	LIVETINF	Char	1	\$X1457X.	\$1.	Liver Etiology Infection
39	LIVETVOD	Char	1	\$X1457X.	\$1.	Liver Etiology VOD
40	LIVETOTH	Char	1	\$X1457X.	\$1.	Liver Etiology Other
41	GVHLIVRS	Char	50	\$50.	\$50.	Liver Etiology Specify
42	GVHLIVRB	Char	1	\$X1822X.	\$1.	Liver Biopsy Results
43	GVHTHERP	Char	1	\$X1457X.	\$1.	GVHD Treatment Modified?
44	GVHAGENT	Char	1	\$X2166X.	\$1.	Agent Type
45	GVHAGNSP	Char	50	\$50.	\$50.	Specify Agent
46	GVHTRMOD	Char	1	\$X2165X.	\$1.	Modification of Treatment
47	STAGEDT_DAYS	Num	8			Date of GvHD Staging (recode: number of days after consent)
48	GVASSTDT_DAYS	Num	8			Start of GVHD Assmt Period (recode: number of days after consent)
49	GVASENDT_DAYS	Num	8			End of GVHD Assmt Period (recode: number of days after consent)
50	TROUGHDT_DAYS	Num	8			Dt of Most Recent Immun (recode: number of days after consent)

Data Set Name: h02.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	PROTSEG	Char	1	\$1.	\$1.	Protocol Segment
4	VISNO	Char	4	\$4.	\$4.	Visit Number
5	HXXRAMET	Char	1	\$X11437X.	\$1.	Recipient HLA-A Method
6	HXXA1REC	Char	100	\$100.	\$100.	Recipient HLA-A 1
7	HXXA2REC	Char	100	\$100.	\$100.	Recipient HLA-A 2
8	HXXRBMET	Char	1	\$X11437X.	\$1.	Recipient HLA-B Method
9	HXXB1REC	Char	100	\$100.	\$100.	Recipient HLA-B 1
10	HXXB2REC	Char	100	\$100.	\$100.	Recipient HLA-B 2
11	HXXRCMET	Char	1	\$X11437X.	\$1.	Recipient HLA-C Method
12	HXXC1REC	Char	100	\$100.	\$100.	Recipient HLA-C 1
13	HXXC2REC	Char	100	\$100.	\$100.	Recipient HLA-C 2
14	HXXRDMET	Char	1	\$X11437X.	\$1.	Recipient HLA-DRB1 Method
15	HXXD1REC	Char	100	\$100.	\$100.	Recipient HLA-DRB1 1
16	HXXD2REC	Char	100	\$100.	\$100.	Recipient HLA-DRB1 2
17	HXXRQMET	Char	1	\$X11437X.	\$1.	Recipient HLA-DQ Method
18	HXXQ1REC	Char	100	\$100.	\$100.	Recipient HLA-DQB1 1
19	HXXQ2REC	Char	100	\$100.	\$100.	Recipient HLA-DQB1 2
20	HXXDNTYP	Char	1	\$X30306X.	\$1.	Donor Type
21	HXXDAMET	Char	1	\$X11437X.	\$1.	Donor HLA-A Method
22	HXXA1DON	Char	100	\$100.	\$100.	Donor HLA-A 1
23	HXXA2DON	Char	100	\$100.	\$100.	Donor HLA-A 2
24	HXXDBMET	Char	1	\$X11437X.	\$1.	Donor HLA-B Method
25	HXXB1DON	Char	100	\$100.	\$100.	Donor HLA-B 1
26	HXXB2DON	Char	100	\$100.	\$100.	Donor HLA-B2
27	HXXDCMET	Char	1	\$X11437X.	\$1.	Donor HLA-C Method
28	HXXC1DON	Char	100	\$100.	\$100.	Donor HLA-C 1
29	HXXC2DON	Char	100	\$100.	\$100.	Donor HLA-C 2
30	HXXDDMET	Char	1	\$X11437X.	\$1.	Donor HLA-DRB1 Method
31	HXXD1DON	Char	100	\$100.	\$100.	Donor HLA-DRB1 1
32	HXXD2DON	Char	100	\$100.	\$100.	Donor HLA-DRB1 2
33	HXXDQMET	Char	1	\$X11437X.	\$1.	Donor HLA-DQ Method
34	HXXQ1DON	Char	100	\$100.	\$100.	Donor HLA-DQB1 1
35	HXXQ2DON	Char	100	\$100.	\$100.	Donor HLA-DQB1 2
36	HXXHRQD	Char	5	\$5.	\$5.	Score Required by Prot

Num	Variable	Type	Len	Format	Informat	Label
37	HXXSCRA	Char	3	\$3.	\$3.	Locus A Calculated Score
38	HXXSCRB	Char	3	\$3.	\$3.	Locus B Calculated Score
39	HXXSCRC	Char	3	\$3.	\$3.	Locus C Calculated Score
40	HXXSCRD	Char	3	\$3.	\$3.	Locus D Calculated Score
41	HXXSCRQ	Char	3	\$3.	\$3.	Locus Q Calculated Score
42	HXXHLA	Char	5	\$5.	\$5.	Total Calculated Score
43	HXXSISC	Char	5	\$X35021X.	\$5.	Institution's Match Score

Data Set Name: hf1.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	PROTSEG	Char	1	\$1.	\$1.	Protocol Segment
4	VISNO	Char	4	\$4.	\$4.	Visit Number
5	ANCDRP	Char	1	\$X1457X.	\$1.	Patient's ANC Drop
6	ANCREC	Char	1	\$X1645X.	\$1.	ANC Recovery 500
7	D1ANC	Num	8	6.	6.	Day 1 ANC
8	D2ANC	Num	8	6.	6.	Day 2 ANC
9	D3ANC	Num	8	6.	6.	Day 3 ANC
10	RECNTANC	Num	8	6.	6.	Most Recent ANC Count
11	MRWCHIM	Char	1	\$X1457X.	\$1.	Chimerism Assay Marrow
12	MRWMTHD	Char	1	\$X1500X.	\$1.	Marrow Method Collection
13	MRWMTHSP	Char	45	\$45.	\$45.	Marrow Specify Method
14	MRWTYPE	Char	1	\$X4469X.	\$1.	Marrow Cell Type
15	MRWRSLT	Char	1	\$X1522X.	\$1.	Marrow Assay Results
16	MRWPCTD	Num	8	3.	3.	Marrow Percent Donor
17	BLDCHIM	Char	1	\$X1457X.	\$1.	Chimerism Assay Blood
18	BLDMTHD	Char	1	\$X1500X.	\$1.	Blood Method Collection
19	BLDMTHSP	Char	45	\$45.	\$45.	Blood Specify Method
20	BLDTYPE	Char	1	\$X4469X.	\$1.	Blood Cell Type
21	BLDRSLT	Char	1	\$X1522X.	\$1.	Blood Assay Results
22	BLDPCTD	Num	8	3.	3.	Blood Percent Donor
23	TCLCHIM	Char	1	\$X1457X.	\$1.	Chimerism Assay T Cell
24	TCLMTHD	Char	1	\$X1500X.	\$1.	T Cell Method Collection
25	TCLMTHSP	Char	45	\$45.	\$45.	T Cell Specify Method
26	TCLTYPE	Char	1	\$X4470X.	\$1.	T Cell Sample Type
27	TCLRSLT	Char	1	\$X1522X.	\$1.	T Cell Assay Results
28	TCLPCTD	Num	8	3.	3.	T Cell Percent Donor
29	D1ANCDT_DAYS	Num	8			Day 1 ANC Date (recode: number of days after consent)
30	D2ANCDT_DAYS	Num	8			Day 2 ANC Date (recode: number of days after consent)
31	D3ANCDT_DAYS	Num	8			Day 3 ANC Date (recode: number of days after consent)
32	RCTANCDT_DAYS	Num	8			Most Recent ANC Date (recode: number of days after consent)
33	MRWCHIDT_DAYS	Num	8			Marrow Collection Date (recode: number of days after consent)
34	BLDCHIDT_DAYS	Num	8			Blood Collection Date (recode: number of days after consent)
35	TCLCHIDT_DAYS	Num	8			T Cell Collection Date (recode: number of days after consent)

Data Set Name: ifn.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	PROTSEG	Char	1	\$1.	\$1.	Protocol Segment
4	INFSITE	Char	2	\$XINFSITEX.	\$2.	Infection Site
5	IFN1NMCR	Char	1	\$X1457X.	\$1.	Infect 1 Nonmicrobiologic
6	IFN1PTPN	Char	1	\$X1457X.	\$1.	Infect 1 Pt Pneumonia
7	IFN1PTVT	Char	1	\$X1457X.	\$1.	Infect 1 Pt Ventilation
8	IFN1PTTY	Char	1	\$X1457X.	\$1.	Infect 1 Pt Typhlitis
9	IFN1PSEP	Char	1	\$X1457X.	\$1.	Infect 1 Pt Severe Sepsis
10	IFN1TYPE	Char	1	\$X1507X.	\$1.	Infection 1 Type
11	IFN1ORGN	Char	3	\$X1371X.	\$3.	Infection 1 Organism
12	IFN1OTSP	Char	50	\$50.	\$50.	Infection 1 Other Specify
13	IFN1SVRT	Char	1	\$X28311X.	\$1.	Infection 1 Severity
14	IFN1EVSP	Char	1	\$X1457X.	\$1.	Infect 1 Evidence Sepsis
15	IFN1EVIN	Char	1	\$X1457X.	\$1.	Infect 1 Evid Infiltrates
16	IFN2NMCR	Char	1	\$X1457X.	\$1.	Infect 2 Nonmicrobiologic
17	IFN2TYPE	Char	1	\$X1507X.	\$1.	Infection 2 Type
18	IFN2ORGN	Char	3	\$X1371X.	\$3.	Infection 2 Organism
19	IFN2OTSP	Char	50	\$50.	\$50.	Infection 2 Other Specify
20	IFN2SVRT	Char	1	\$X28311X.	\$1.	Infection 2 Severity
21	IFN2EVSP	Char	1	\$X1457X.	\$1.	Infect 2 Evidence Sepsis
22	IFN2EVIN	Char	1	\$X1457X.	\$1.	Infect 2 Evid Infiltrates
23	IFN3NMCR	Char	1	\$X1457X.	\$1.	Infect 3 Nonmicrobiologic
24	IFN3TYPE	Char	1	\$X1507X.	\$1.	Infection 3 Type
25	IFN3ORGN	Char	3	\$X1371X.	\$3.	Infection 3 Organism
26	IFN3SVRT	Char	1	\$X28311X.	\$1.	Infection 3 Severity
27	IFN3EVSP	Char	1	\$X1457X.	\$1.	Infect 3 Evidence Sepsis
28	IFN3EVIN	Char	1	\$X1457X.	\$1.	Infect 3 Evid Infiltrates
29	IFNAGTRT	Char	1	\$X1457X.	\$1.	Agent Given to Treat Inf
30	IFN1AGNT	Char	50	\$X2850X.	\$50.	1st Agent Given
31	IFN1AGSP	Char	50	\$50.	\$50.	1st Agent Other Specify
32	IFN2AGNT	Char	50	\$X2850X.	\$50.	2nd Agent Given
33	IFN2AGSP	Char	50	\$50.	\$50.	2nd Agent Other Specify
34	IFN3AGNT	Char	50	\$X2850X.	\$50.	3rd Agent Given
35	IFN3AGSP	Char	50	\$50.	\$50.	3rd Agent Other Specify
36	IFNADDAG	Char	1	\$X1457X.	\$1.	Additional Agent Given

Num	Variable	Type	Len	Format	Informat	Label
37	IFNADDSP	Char	50	\$50.	\$50.	Additional Agent Specify
38	INFSTDT_DAYS	Num	8			Infection Start Date (recode: number of days after consent)

Data Set Name: io1.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	PROTSEG	Char	1	\$1.	\$1.	Protocol Segment
4	IO1REASN	Char	2	\$X36645X.	\$2.	Unsched Shipment Reason
5	IO1OTHSP	Char	50	\$50.	\$50.	Other Reason Specify
6	IO1DOSE	Char	1	\$X36643X.	\$1.	Dose
7	IO1CYCLE	Num	8	2.	2.	Number of Cycles Needed
8	REQUESDT_DAYS	Num	8			Date Drug Order Request (recode: number of days after consent)

Data Set Name: iof.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	PROTSEG	Char	1	\$1.	\$1.	Protocol Segment
4	VISNO	Char	4	\$4.	\$4.	Visit Number
5	IOFDISTP	Char	1	\$X1457X.	\$1.	Discontinued Therapy
6	IOFDISRN	Char	2	\$X36642X.	\$2.	Discontinued Reason
7	IOFOTHSP	Char	50	\$50.	\$50.	Other Reason Specify
8	IOFCYCLE	Num	8	3.	3.	Next Cycle Number
9	IOFDOSE	Char	1	\$X36643X.	\$1.	Dose
10	IOFCYCDT_DAYS	Num	8			Next Cycle Start Date (recode: number of days after consent)

Data Set Name: min.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	PROTSEG	Char	1	\$1.	\$1.	Protocol Segment
4	VISNO	Char	4	\$4.	\$4.	Visit Number
5	MINMTINI	Char	1	\$X1457X.	\$1.	Maintenance Initiated
6	MINMTDT_DAYS	Num	8			Maintenance Therapy Date (recode: number of days after consent)

Data Set Name: mpf.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	PROTSEG	Char	1	\$1.	\$1.	Protocol Segment
4	VISNO	Char	4	\$4.	\$4.	Visit Number
5	MPHCTCIS	Num	8	3.	3.	HCT Comorbidity Score
6	MPSTATUS	Char	1	\$X36770X.	\$1.	Disease Status
7	MPSPEP	Char	1	\$X1457X.	\$1.	SPEP Performed
8	MPSPTPG	Num	8	8.3	8.3	SPEP Total Protein Gram
9	MPSPRES	Char	1	\$X19936X.	\$1.	SPEP M-Protein Result
10	MPSPMSG	Num	8	8.3	8.3	SPEP M-Protein Gram
11	MPSPTPMG	Num	8	10.2	10.2	SPEP Total Protein mg
12	MPSPMSG	Num	8	10.2	10.2	SPEP M-Protein mg
13	MPSIFE	Char	1	\$X1457X.	\$1.	Serum IFE Performed
14	MPSIFERS	Char	1	\$X36803X.	\$1.	Serum IFE Result
15	MPSIFEBD	Char	1	\$X36804X.	\$1.	Serum IFE Bands Present
16	MPSFLC	Char	1	\$X1457X.	\$1.	Serum FLC Measured
17	MPKFLCL	Num	8	11.2	11.2	Kappa FLC mg/L
18	MPLFLCL	Num	8	11.2	11.2	Lambda FLC mg/L
19	MPSFLCRT	Num	8	15.6	15.6	Kappa/Lambda FLC Ratio
20	MPKFLCDL	Num	8	11.3	11.3	Kappa FLC mg/dL
21	MPLFLCDL	Num	8	11.3	11.3	Lambda FLC mg/dL
22	MPUPEP	Char	1	\$X1457X.	\$1.	UPEP Performed
23	MPNOUPEP	Char	70	\$70.	\$70.	UPEP Reason Missing
24	MPUPTPG	Num	8	9.3	9.3	UPEP Total Protein Grams
25	MPUPTVL	Num	8	8.3	8.3	UPEP Total Volume L
26	MPUPRES	Char	1	\$X19936X.	\$1.	UPEP M-Protein Result
27	MPUPMSG	Num	8	9.3	9.3	UPEP M-Protein Grams
28	MPUPTPMG	Num	8	11.2	11.2	UPEP Total Protein mg
29	MPUPTVML	Num	8	10.2	10.2	UPEP Total Volume ml
30	MPUPMSG	Num	8	11.2	11.2	UPEP M-Protein mg
31	MPUIFE	Char	1	\$X1457X.	\$1.	Urine IFE Performed
32	MPNOUIFE	Char	70	\$70.	\$70.	Urine IFE Reason Missing
33	MPUIFERS	Char	1	\$X36803X.	\$1.	Urine IFE Results
34	MPUIFEBD	Char	1	\$X36804X.	\$1.	Urine IFE Bands
35	MPSRIGS	Char	1	\$X1457X.	\$1.	Immunoglobulins Obtained
36	MPSIGG	Num	8	10.2	10.2	Quantitative IgG

Num	Variable	Type	Len	Format	Informat	Label
37	MPSIGA	Num	8	10.2	10.2	Quantitative IgA
38	MPSIGM	Num	8	10.2	10.2	Quantitative IgM
39	MPSIGE	Num	8	8.1	8.1	Quantitative IgE
40	MPBMBX	Char	1	\$X1457X.	\$1.	BMBX Performed
41	MPBMBXRS	Char	1	\$X19936X.	\$1.	BMBX Plasma Cells Present
42	MPBMBXPC	Num	8	7.1	7.1	BMBX Plasma Cells Percent
43	MPBMBA	Char	1	\$X1457X.	\$1.	BMA Performed
44	MPBMARS	Char	1	\$X19936X.	\$1.	BMA Plasma Cells Present
45	MPBMAPC	Num	8	7.1	7.1	BMA Plasma Cells Percent
46	MPIHC	Char	1	\$X1635X.	\$1.	IHC Performed
47	MPIHCRES	Char	1	\$X36821X.	\$1.	IHC Results
48	MPIHCSP	Char	70	\$70.	\$70.	IHC Results Specify
49	MPSKELSR	Char	1	\$X1457X.	\$1.	Skeletal Bone Survey
50	MPSKELSE	Char	1	\$X1457X.	\$1.	Skeletal Bone Survey Init
51	MPSKELRS	Char	1	\$X36774X.	\$1.	Skeletal Bone Results
52	MPSKELOT	Char	70	\$70.	\$70.	Skeletal Bone Results Spe
53	MPCTPET	Char	1	\$X1457X.	\$1.	CT/PET Scan Done
54	MPCTPTSE	Char	1	\$X1457X.	\$1.	CT/PET Scan Study Entry
55	MPCTPTRS	Char	1	\$X36822X.	\$1.	CT/PET Scan Results
56	MPCTPTSP	Char	70	\$70.	\$70.	CT/PET Results Specify
57	MPCLBM	Char	1	\$X36823X.	\$1.	PC Flow Cytometry
58	MPCLBMPC	Num	8	7.1	7.1	PC Flow Cytometry Percent
59	MPCLPB	Char	1	\$X36823X.	\$1.	PC Peripheral Blood
60	MPSTRTDT_DAYS	Num	8			Assessment Period Start (recode: number of days after consent)
61	MPENDDT_DAYS	Num	8			Assessment Period End (recode: number of days after consent)
62	MPSPEPDT_DAYS	Num	8			SPEP Date (recode: number of days after consent)
63	MPSIFEDT_DAYS	Num	8			Serum IFE Date (recode: number of days after consent)
64	MPSFLCDT_DAYS	Num	8			Serum FLC Date (recode: number of days after consent)
65	MPUPEPDT_DAYS	Num	8			UPEP Date (recode: number of days after consent)
66	MPUIFEDT_DAYS	Num	8			Urine IFE Date (recode: number of days after consent)
67	MPSRIGDT_DAYS	Num	8			Immunoglobulins Date (recode: number of days after consent)
68	MPBMBXDT_DAYS	Num	8			BMBX Date (recode: number of days after consent)
69	MPBMADT_DAYS	Num	8			BMA Date (recode: number of days after consent)
70	MPSKELDT_DAYS	Num	8			Skeletal Bone Survey Date (recode: number of days after consent)
71	MPCTPTDT_DAYS	Num	8			CT/PET Scan Date (recode: number of days after consent)
72	MPCLBMDT_DAYS	Num	8			PC Flow Cytometry Date (recode: number of days after consent)

Data Set Name: outcome.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	TRTCODE	Char	6			Randomized Treatment Assignment Code
3	TREAT	Char	1			Treatment Group Number
4	TREATMENT	Char	50			Treatment Assignment
5	TREATMENT2	Char	50			Transplant/Randomization Treatment Status
6	TXP	Num	8	YESNO.		Subject Transplanted
7	ENR_POSTHOLD	Num	8	YESNO.		Enrolled Post Study Hold
8	RAND	Char	1	\$YNM.		Subject Randomized
9	NONRAND_REASON	Char	40			Reason Not Randomized
10	ORDERDEATH	Num	8	DEATHO.		Primary Cause of Death
11	DIED_POSTHOLD_E	Num	8	YESNO.		Died Enrolled Post Study Hold
12	DIED_POSTHOLD_T	Num	8	YESNO.		Died Enrolled Post Study Hold and Transplanted
13	DIED_POSTHOLD_R	Num	8	YESNO.		Died Enrolled Post Study Hold and Randomized
14	AGE	Num	8			Age at Enrollment
15	GENDER2	Char	1	\$GENDERF.		Gender
16	ETHNIC	Char	3	\$ETHNICF.	\$3.	Ethnicity
17	AMADISC	Char	1	\$DISTAT.	\$1.	Disease Classification
18	AMAPRPRG	Char	1	\$NUMBPROG.	\$1.	Number of Progressions
19	AMAPRAUT	Char	1	\$YNM.	\$1.	Prior Auto Transplant
20	AMAKPS	Char	2	\$PSBF.	\$2.	Karnofsky Score
21	AMAALLO	Char	1	\$YNM.	\$1.	Prior Allo HCT
22	AMADTYPE	Char	1	\$DONTYPE.	\$1.	Donor Type
23	AMA13DEL	Char	1	\$YNM.	\$1.	Deletion of Chromo 13
24	AMAHYPOD	Char	1	\$YNM.	\$1.	Presence of Hypodiploidy
25	AMA1ABNO	Char	1	\$YNM.	\$1.	Abnormality in Chromo 1
26	AMA17DEL	Char	1	\$YNM.	\$1.	Deletion of 17p
27	AMAGEP	Char	1	\$YNM.	\$1.	High Risk by GEP
28	CMVSTAT	Char	1	\$CMVSTATUS.	\$1.	CMV Status
29	RESPONSECODE	Char	1	\$RESP.		Disease Status at Enrollment
30	MAXGRADE	Char	1			Maximum Grade of Acute GVHD Through Day 100 Post-transplant
31	IOFDISTPR	Char	1	\$YNM.	\$1.	Randomized Maintenance Therapy Discontinued
32	IOFDISRN	Char	2	\$X36642X.	\$2.	Reason Randomized Maintenance Discontinued
33	IOFOTHSP	Char	50	\$50.	\$50.	Specify Other Reason Randomized Maintenance Discontinued
34	DISCVIS	Char	4			Visit Randomized Maintenance Discontinued
35	RESP_RAND	Char	1	\$RESPEC.	\$1.	Disease Response at Randomization

Num	Variable	Type	Len	Format	Informat	Label
36	RESP_STRATA	Char	1	\$SYNM.		In sCR/CR at Randomization
37	RESP_T_D60	Char	1	\$RESPC.		Disease Response at Day 60 Post-transplant
38	RESP_T18	Char	1	\$RESPC.		Disease Response at Month 18 Post-transplant
39	RESP_T24	Char	1	\$RESPC.		Disease Response at Month 24 Post-transplant
40	RESP_R	Char	1	\$RESPC.		Best Disease Response After Randomization
41	MAXTOX	Num	8			Maximum Grade 3-5 toxicity Post-randomization
42	PFSE_SRVTM	Num	8			Days of Progression-free Survival Post-enrollment
43	PFSE_MON	Num	8			Months of Progression-free Survival Post-enrollment
44	PFSE_CI	Num	8			Indicator for Progression-free Survival Post-enrollment
45	PFSE_EVENT	Num	8	PFS_EVT.		Progression-free Survival Outcome Post-enrollment
46	OSE_SRVTM	Num	8			Days of Overall Survival Post-enrollment
47	OSE_MON	Num	8			Months of Overall Survival Post-enrollment
48	OSE_EVENT	Num	8	OS_EVT.		Overall Survival Outcome Post-enrollment
49	PFST_SRVTM	Num	8			Days of Progression-free Survival Post-transplant
50	PFST_MON	Num	8			Months of Progression-free Survival Post-transplant
51	PFST_CI	Num	8			Indicator of Progression-free Survival Post-transplant
52	PFST_EVENT	Num	8	PFS_EVT.		Progression-free Survival Outcome Post-transplant
53	OST_SRVTM	Num	8			Days of Overall Survival Post-transplant
54	OST_MON	Num	8			Months of Overall Survival Post-transplant
55	OST_EVENT	Num	8	OS_EVT.		Overall Survival Outcome Post-transplant
56	AGVH34TDAY	Num	8			Days to Grade III-IV aGVHD Post-transplant
57	GVH34T_CI	Num	8			Indicator of Grade III-IV aGVHD Post-transplant
58	CGVHDTDAY	Num	8			Days to Chronic GVHD Post-transplant
59	CGVHDTMON	Num	8			Months to Chronic GVHD Post-transplant
60	CGVHDT_CI	Num	8			Indicator of Chronic GVHD Post-transplant
61	PFSR_SRVTM	Num	8			Days of Progression-free Survival Post-randomization
62	PFSR_MON	Num	8			Months of Progression-free Survival Post-randomization
63	PFSR_CI	Num	8			Indicator of Progression-free Survival Post-randomization
64	PFSR_EVENT	Num	8	PFS_EVT.		Progression-free Survival Outcome Post-randomization
65	OSR_SRVTM	Num	8			Days of Overall Survival Post-randomization
66	OSR_MON	Num	8			Months of Overall Survival Post-randomization
67	OSR_EVENT	Num	8	OS_EVT.		Overall Survival Outcome Post-randomization
68	AGVH34RDAY	Num	8			Days to Grade III-IV aGVHD Post-randomization
69	GVH34R_CI	Num	8			Indicator of Grade III-IV aGVHD Post-randomization
70	CGVHDRDAY	Num	8			Days to Chronic GVHD Post-randomization
71	CGVHDRMON	Num	8			Months to Chronic GVHD Post-randomization
72	CGVHDR_CI	Num	8			Indicator of Chronic GVHD Post-randomization
73	IFNRDAY	Num	8			Days to Grade 3 Infection Post-randomization

Num	Variable	Type	Len	Format	Informat	Label
74	IFNRMON	Num	8			Months to Grade 3 Infection Post-randomization
75	IFNR_CI	Num	8			Indicator of Grade 3 Infection Post-randomization
76	TOXRDAY	Num	8			Days to Grade 3 to 5 Toxicity Post-randomization
77	TOXRMON	Num	8			Months to Grade 3 to 5 Toxicity Post-randomization
78	TOXR_CI	Num	8			Indicator of Grade 3 to 5 Toxicity Post-randomization
79	PROG_POSTHOLD_E	Num	8	YESNO.		Progression Enrolled Post Study Hold
80	PROG_POSTHOLD_T	Num	8	YESNO.		Progression Enrolled Post Study Hold and Transplanted
81	PROG_POSTHOLD_R	Num	8	YESNO.		Progression Enrolled Post Study Hold and Randomized
82	FACT_BMT_TOTAL_0000	Num	8			FACT-BMT Total Score: 0000
83	FACT_BMT_TOTAL_PRV	Num	8			FACT-BMT Total Score: PRV
84	FACT_BMT_TOTAL_0169	Num	8			FACT-BMT Total Score: 0169
85	FACT_BMT_TOTAL_PMV	Num	8			FACT-BMT Total Score: PMV
86	FACT_BMT_TOTAL_T24M	Num	8			FACT-BMT Total Score: T24M
87	PCS_0000	Num	8			SF36-PCS: 0000
88	PCS_PRV	Num	8			SF36-PCS: PRV
89	PCS_0169	Num	8			SF36-PCS: 0169
90	PCS_PMV	Num	8			SF36-PCS: PMV
91	PCS_T24M	Num	8			SF36-PCS: T24
92	MCS_0000	Num	8			SF36-MCS: 0000
93	MCS_PRV	Num	8			SF36-MCS: PRV
94	MCS_0169	Num	8			SF36-MCS: 0169
95	MCS_PMV	Num	8			SF36-MCS: PMV
96	MCS_T24M	Num	8			SF36-MCS: T24
97	MRD_0000	Char	1	\$1.		MRD Conclusion: 0000
98	MRD_PRV	Char	1	\$1.		MRD Conclusion: PRV
99	MRD_PMV	Char	1	\$1.		MRD Conclusion: PMV
100	ENRLDATE_DAYS	Num	8			Enrollment Date (recode: number of days after consent)
101	ENRLDATE_B_DAYS	Num	8			Randomization Date (recode: number of days after consent)
102	FUDATE_DAYS	Num	8			Date of Last Follow Up (recode: number of days after consent)
103	TXDTPXP_DAYS	Num	8			Transplant Date (recode: number of days after consent)
104	STAGEDT_34T_DAYS	Num	8			Date of Grade III-IV aGVHD Post-transplant (recode: number of days after consent)
105	STAGEDT_34R_DAYS	Num	8			Date of Grade III-IV aGVHD Post-randomization (recode: number of days after consent)
106	PRRELPDTP_DAYS	Num	8			Date of Progression Post-transplant (recode: number of days after consent)
107	PRRELPDTR_DAYS	Num	8			Date of Progression Post-randomization (recode: number of days after consent)

Num	Variable	Type	Len	Format	Informat	Label
108	FGCGDGDTT_DAYS	Num	8			Date of Chronic GVHD Post-transplant (recode: number of days after consent)
109	FGCGDGDTR_DAYS	Num	8			Date of Chronic GVHD Post-randomization (recode: number of days after consent)
110	INFSTDTR_DAYS	Num	8			Date of Grade 3 Infection Post-randomization (recode: number of days after consent)
111	TXYEVLDT_DAYS	Num	8			Grade 3-5 toxicity onset Post-randomization (recode: number of days after consent)
112	PRRELPDTE_DAYS	Num	8			Date of Progression Post-enrollment (recode: number of days after consent)
113	DTHDT_DAYS	Num	8			Date of Death (recode: number of days after consent)

Data Set Name: pcg.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	PROTSEG	Char	1	\$1.	\$1.	Protocol Segment
4	VISNO	Char	4	\$4.	\$4.	Visit Number
5	PCGSKIN	Char	1	\$X18312X.	\$1.	PCG Skin Score
6	PCGMOUTH	Char	1	\$X18334X.	\$1.	PCG Mouth Score
7	PCGGITRC	Char	1	\$X18350X.	\$1.	PCG GI Tract Score
8	PCGEYE	Char	1	\$X18354X.	\$1.	PCG Eye Score
9	PCGJOINT	Char	1	\$X28972X.	\$1.	PCG Joint / Fascia Score
10	PCGNOEXM	Char	1	\$X29029X.	\$1.	PCG No GYN Exam
11	PCGGNITL	Char	1	\$X18356X.	\$1.	PCG Genital Tract Score
12	PCGLUNG	Char	1	\$X18358X.	\$1.	PCG Lung Score
13	PCGSEV1	Char	1	\$X19005X.	\$1.	PCG Severity Scale 1
14	PCGSEV2	Char	2	\$X28973X.	\$2.	PCG Severity Scale 2
15	PCGRASH	Char	1	\$X1457X.	\$1.	PCG Eryth/Maculopap Rash
16	PCGVOMIT	Char	1	\$X1457X.	\$1.	PCG Nausea, Vomit, Diarrh
17	PCGLIVER	Char	1	\$X28962X.	\$1.	PCG Liver Score
18	PCGFEV1	Num	8	4.	4.	PCG FEV1
19	PCGFEVND	Char	1	\$X28970X.	\$1.	PCG FEV1 Not Done
20	PCGDLCO	Num	8	4.	4.	PCG DLCOc
21	PCGDLCND	Char	1	\$X28970X.	\$1.	PCG DLCOc Not Done
22	PCGDATE_DAYS	Num	8			PCG Date of Visit (recode: number of days after consent)
23	PCGLFTDT_DAYS	Num	8			PCG LFT Sample Date (recode: number of days after consent)
24	PCGFEVDT_DAYS	Num	8			PCG Date of FEV1 (recode: number of days after consent)
25	PCGDLCDT_DAYS	Num	8			PCG Date of DLCOc (recode: number of days after consent)

Data Set Name: pdr.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	PROTSEG	Char	1	\$1.	\$1.	Protocol Segment
4	PDSEQNUM	Char	2	\$XPDSEQX.	\$2.	Deviation/Violation Num
5	PDREVSUM	Char	551	\$551.	\$2000.	Event Summary
6	PDRQUAL	Char	1	\$X1457X.	\$1.	Event Qualification
7	PDRCATEG	Char	11	\$X41403X.	\$11.	Deviation Category
8	PDRREASN	Char	10	\$X41406X.	\$10.	Reason For Deviation
9	PDRDSMB	Char	1	\$X1457X.	\$1.	DSMB Reportable
10	PDRDSMSF	Char	2	\$X43909X.	\$2.	DSMB Spring Fall
11	PDRDSMYR	Num	8	5.	5.	DSMB Year
12	PDRCCCPR	Char	1	\$X1457X.	\$1.	Center Perform Report
13	PDRCAPA	Char	1	\$X1457X.	\$1.	Site Re-training CAPA
14	PDRCAPSP	Char	270	\$270.	\$2000.	CAPA Specify
15	PDRRECOM	Char	1	\$X1457X.	\$1.	Review Complete
16	PDRPDREV	Char	1	\$X1457X.	\$1.	Project Director Reviewed
17	PDRGMREV	Char	1	\$X1457X.	\$1.	Group Manager Reviewed
18	PDREVDT_DAYS	Num	8			Event Review Date (recode: number of days after consent)
19	PDDATE_DAYS	Num	8			Deviation/Violation Date (recode: number of days after consent)

Data Set Name: pdv.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	PROTSEG	Char	1	\$1.	\$1.	Protocol Segment
4	PDSEQNUM	Char	2	\$XPDSEQX.	\$2.	Deviation/Violation Num
5	PDVCATEG	Char	2	\$X41403X.	\$2.	Deviation Category
6	PDVCATSP	Char	50	\$50.	\$50.	Deviation Categor Specify
7	PDVREASO	Char	2	\$X41406X.	\$2.	Deviation Reason
8	PDVREASP	Char	50	\$50.	\$50.	Deviation Reason Specify
9	PDVSTDIS	Char	1	\$X1457X.	\$1.	Deviation Therapy Discont
10	PDVIRBRE	Char	1	\$X1457X.	\$1.	Deviation IRB reported
11	PDVIRBOU	Char	1	\$X41572X.	\$1.	Deviation IRB outcome
12	PDVCORRC	Char	1	\$X1457X.	\$1.	Deviation Corrective Act
13	PDVIDTDT_DAYS	Num	8			Date Deviation Identified (recode: number of days after consent)
14	PDVIRBDT_DAYS	Num	8			Deviation IRB Report Date (recode: number of days after consent)
15	PDDATE_DAYS	Num	8			Deviation/Violation Date (recode: number of days after consent)

Data Set Name: pgf.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	PROTSEG	Char	1	\$1.	\$1.	Protocol Segment
4	PGSPEPYN	Char	1	\$X3613X.	\$1.	SPEP Progression Indicate
5	PGSFLCYN	Char	1	\$X3613X.	\$1.	FLC Progression Indicated
6	PGSIFEYN	Char	1	\$X3613X.	\$1.	SIFE Progression Indicate
7	PGUPEPYN	Char	1	\$X3613X.	\$1.	UPEP Progression Indicate
8	PGUIFEYN	Char	1	\$X3613X.	\$1.	UIFE Progression Indicate
9	PGBMYN	Char	1	\$X3613X.	\$1.	Marrow Progression Indica
10	PGLESNYN	Char	1	\$X3613X.	\$1.	Lesion Progression Indica
11	PGPLCYYN	Char	1	\$X3613X.	\$1.	Plasmacytoma Progression
12	PGCALCYN	Char	1	\$X3613X.	\$1.	Calcium Progression Indic
13	PGSPEP	Char	1	\$X1457X.	\$1.	SPEP Performed
14	PGSTPTG	Num	8	8.3	8.3	SPEP Total g/dL
15	PGSPRES	Char	1	\$X38719X.	\$1.	SPEP Spike Result
16	PGSPMSG	Num	8	8.3	8.3	SPEP Spike g/dL
17	PGSPTMG	Num	8	10.2	10.2	SPEP Total mg/dL
18	PGSPMSMG	Num	8	10.2	10.2	SPEP Spike mg/dL
19	PGSIFE	Char	1	\$X1457X.	\$1.	SIFE Performed
20	PGSIFERS	Char	1	\$X36803X.	\$1.	SIFE Result
21	PGSIFEBD	Char	1	\$X38748X.	\$1.	Serum IFE Bands
22	PGSFLC	Char	1	\$X1457X.	\$1.	Serum FLC
23	PGKFLCL	Num	8	11.2	11.2	Kappa FLC Value mg/L
24	PGLFLCL	Num	8	11.2	11.2	Lambda FLC Value mg/L
25	PGSFLCRT	Num	8	15.6	15.6	Serum FLC Ratio
26	PGKFLCDL	Num	8	11.3	11.3	Kappa FLC Value mg/dL
27	PGLFLCDL	Num	8	11.3	11.3	Lambda FLC Value mg/dL
28	PGUPEP	Char	1	\$X1457X.	\$1.	UPEP Performed
29	PGUPTPG	Num	8	9.3	9.3	UPEP Total g/24h
30	PGUPTL	Num	8	8.3	8.3	UPEP Volume L
31	PGUPRES	Char	1	\$X38719X.	\$1.	UPEP M Result
32	PGUPMG	Num	8	9.3	9.3	UPEP Spike g/24hr
33	PGUPTPMG	Num	8	11.2	11.2	UPEP Total mg/24hr
34	PGUPTVML	Num	8	10.2	10.2	UPEP Volume ml/24hr
35	PGUPMSMG	Num	8	11.2	11.2	UPEP Spike mg/24hr
36	PGUIFE	Char	1	\$X1457X.	\$1.	UIFE Performed

Num	Variable	Type	Len	Format	Informat	Label
37	PGUIFERS	Char	1	\$X36803X.	\$1.	UIFE Result
38	PGUIFEBD	Char	1	\$X38748X.	\$1.	UIFE Bands
39	PGSRIGS	Char	1	\$X1457X.	\$1.	Immunoglobulins Performed
40	PGSIGG	Num	8	10.2	10.2	IgG Value mg/dL
41	PGSIGA	Num	8	10.2	10.2	IgA Value mg/dL
42	PGSIGM	Num	8	10.2	10.2	IgM Value mg/dL
43	PGSIGD	Num	8	8.3	8.3	IgD Value mg/dL
44	PGSIGE	Num	8	8.1	8.1	IgE Value mg/dL
45	PGBMBX	Char	1	\$X1457X.	\$1.	Bone Marrow Biopsy Done
46	PGBMBXRS	Char	1	\$X38719X.	\$1.	BM Plasma Cell Result
47	PGBMBXPC	Num	8	7.1	7.1	BM Biopsy Percent Cells
48	PGBMBA	Char	1	\$X1457X.	\$1.	Bone Marrow Aspirate Done
49	PGBMBARS	Char	1	\$X38719X.	\$1.	BM Aspirate Result
50	PGBMBAPC	Num	8	7.1	7.1	BM Aspirate Percent Cells
51	PGSKELSR	Char	1	\$X1457X.	\$1.	Bone Survey Performed
52	PGSKELRS	Char	1	\$X38771X.	\$1.	Bone Survey Results
53	PGSKELSP	Char	50	\$50.	\$50.	Bone Survey Reslt Specify
54	PGCTPET	Char	1	\$X1457X.	\$1.	CT PET Scan Performed
55	PGCTPTRS	Char	1	\$X38772X.	\$1.	CT PET Results
56	PGCTPSP	Char	50	\$50.	\$50.	CT PET Other Specify
57	PGFCALC	Char	1	\$X1457X.	\$1.	Corrected Serum Calcium
58	PGFCAVAL	Num	8	7.2	7.2	Serum Calcium Value
59	PGFCAUN	Char	1	\$X20623X.	\$1.	Serum Calcium Units
60	PGHYPCAL	Char	1	\$X1457X.	\$1.	Developed Hypercalcemia
61	PGHYPATT	Char	1	\$X1457X.	\$1.	Hypercalcemia Attributed
62	PGFTREAT	Char	1	\$X1457X.	\$1.	Treated For Progression
63	PGFRTTYP	Char	1	\$X20621X.	\$1.	Progression Treat Type
64	PGFTRTSP	Char	50	\$50.	\$50.	Specify Other Treatment
65	PGCLBM	Char	1	\$X38773X.	\$1.	Flow Cytometry Performed
66	PGCLBMPC	Num	8	7.1	7.1	Flow Cyto Plasm Cell Perc
67	PGCLPB	Char	1	\$X38773X.	\$1.	Peripheral Blood Sample
68	PGCLBPPC	Num	8	7.1	7.1	Peripherl Plasm Cell Perc
69	PRREL PDT_DAYS	Num	8			Progression/Relapse Date (recode: number of days after consent)
70	PGSPEPDT_DAYS	Num	8			SPEP Date (recode: number of days after consent)
71	PGSIFEDT_DAYS	Num	8			SIFE Date (recode: number of days after consent)
72	PGSFLCDT_DAYS	Num	8			Serum FLC Date (recode: number of days after consent)
73	PGUPEPDT_DAYS	Num	8			UPEP Date (recode: number of days after consent)
74	PGUIFEDT_DAYS	Num	8			UIFE Date (recode: number of days after consent)
75	PGSIRGDT_DAYS	Num	8			Immunoglobulins Date (recode: number of days after consent)

Num	Variable	Type	Len	Format	Informat	Label
76	PGBMBXDT_DAYS	Num	8			Bone Marrow Biopsy Date (recode: number of days after consent)
77	PGBMBADT_DAYS	Num	8			Bone Marrow Aspirate Date (recode: number of days after consent)
78	PGSKLEDT_DAYS	Num	8			Bone Survey Date (recode: number of days after consent)
79	PGCTPTDT_DAYS	Num	8			CT PET Scan Date (recode: number of days after consent)
80	PGFCADT_DAYS	Num	8			Serum Calcium Date (recode: number of days after consent)
81	PGFTRTDT_DAYS	Num	8			Progression Treat Date (recode: number of days after consent)
82	PGBMCLDT_DAYS	Num	8			Flow Cytometry Date (recode: number of days after consent)
83	PGCLBPDТ_DAYS	Num	8			Peripheral Blood Date (recode: number of days after consent)

Data Set Name: psf.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	PROTSEG	Char	1	\$1.	\$1.	Protocol Segment
4	STATUS	Char	2	\$XSTATUSX.	\$2.	Status
5	STATSEQ	Char	2	\$XSEQNUMX.	\$2.	Status Change Number
6	PSWDRSN	Char	100	\$100.	\$100.	Reason For Withdrawal
7	PSWDDRG	Char	1	\$X1457X.	\$1.	Withdrawal Discon Drug
8	PSWDDGNM	Char	50	\$50.	\$50.	Study Drug Name
9	PSDRGRSN	Char	1	\$X41506X.	\$1.	Reason Drug Discontinued
10	PSTXYSP	Char	100	\$100.	\$100.	Specify Toxicity
11	PSDGOTSP	Char	100	\$100.	\$100.	Specify Other
12	PSDRGNM	Char	50	\$50.	\$50.	Study Drug Name
13	PSSEGRSN	Char	1	\$X41507X.	\$1.	Reason Not Proceeding
14	PSELGYSP	Char	100	\$100.	\$100.	Specify Eligibility
15	PSSEGOSP	Char	100	\$100.	\$100.	Specify Other Not Proceed
16	PSTXPRN	Char	1	\$X41508X.	\$1.	Reason For No Transplant
17	PSTXPTSP	Char	100	\$100.	\$100.	Specify Tox No Txp
18	PSWDDT_DAYS	Num	8			Withdrawal Date (recode: number of days after consent)
19	PSWDDGDT_DAYS	Num	8			Last Drug Dose Date (recode: number of days after consent)
20	PSDRGDT_DAYS	Num	8			Last Dose Of Study Drug (recode: number of days after consent)

Data Set Name: s14.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	PROTSEG	Char	1	\$1.	\$1.	Protocol Segment
4	VISNO	Char	4	\$4.	\$4.	Visit Number
5	S14SERUM	Char	1	\$X1457X.	\$1.	Serum Sample
6	S14PBMC	Char	1	\$X1457X.	\$1.	PBMC Sample
7	S14BMASP	Char	1	\$X1457X.	\$1.	Bone Marrow Aspirate
8	S14PBMIR	Char	1	\$X1457X.	\$1.	PBMC for Immune Recon
9	S14BMMRD	Char	1	\$X1457X.	\$1.	Bone Marrow for MRD
10	S14SERDT_DAYS	Num	8			Serum Collection Date (recode: number of days after consent)
11	S14PBMDT_DAYS	Num	8			PBMC Collection Date (recode: number of days after consent)
12	S14BMADT_DAYS	Num	8			Bone Marrow Aspirate Date (recode: number of days after consent)
13	S14BIRDT_DAYS	Num	8			PBMC for Immun Recon Date (recode: number of days after consent)
14	S14MRDDT_DAYS	Num	8			Bone Marrow for MRD Date (recode: number of days after consent)

Data Set Name: sfh.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	PROTSEG	Char	1	\$1.	\$1.	Protocol Segment
4	VISNO	Char	4	\$4.	\$4.	Visit Number
5	GENHLTH	Char	1	\$X3667X.	\$1.	1. General health
6	COMPARE	Char	1	\$X3668X.	\$1.	2. Compare to a year ago
7	VIGOROUS	Char	1	\$X3677X.	\$1.	3a. Vigorous activities
8	MODERATE	Char	1	\$X3677X.	\$1.	3b. Moderate activities
9	LIFTING	Char	1	\$X3677X.	\$1.	3c. Lifting groceries
10	CLINBSEV	Char	1	\$X3677X.	\$1.	3d. Climbing several flig
11	CLIMBONE	Char	1	\$X3677X.	\$1.	3e. Climbing one flight
12	BENDING	Char	1	\$X3677X.	\$1.	3f. Bending or kneeling
13	WALKMILE	Char	1	\$X3677X.	\$1.	3g. Walking more than mi
14	WALKSBLK	Char	1	\$X3677X.	\$1.	3h. Walk several blocks
15	WALK1BLK	Char	1	\$X3677X.	\$1.	3i. Walk one block
16	BATHING	Char	1	\$X3677X.	\$1.	3j. Bathing or dressing
17	CUTTME	Char	1	\$X5712X.	\$1.	4a. Time cut down
18	LESSACC	Char	1	\$X5712X.	\$1.	4b. Less accomplished
19	WORKLMT	Char	1	\$X5712X.	\$1.	4c. Work limited
20	PRFMDIFF	Char	1	\$X5712X.	\$1.	4d. Perform difficulty
21	ECUTTME	Char	1	\$X5712X.	\$1.	5a. Emotion time cut down
22	ELESSACC	Char	1	\$X5712X.	\$1.	5b. Emotion less accompl
23	ECARELES	Char	1	\$X5712X.	\$1.	5c. Emot less careful
24	INTERFER	Char	1	\$X3669X.	\$1.	6. Interefere with normal
25	BODYPAIN	Char	1	\$X3670X.	\$1.	7. Bodily pain
26	WORKPAIN	Char	1	\$X3671X.	\$1.	8. Pain interfere work
27	FULLLIFE	Char	1	\$X5712X.	\$1.	9a. Full of life
28	FEELNERV	Char	1	\$X5712X.	\$1.	9b. Feel nervous
29	FEELDOWN	Char	1	\$X5712X.	\$1.	9c. Feel down in dumps
30	FEELCALM	Char	1	\$X5712X.	\$1.	9d. Feel calm
31	FLEENERGY	Char	1	\$X5712X.	\$1.	9e. Feel a lot of energy
32	FEELDEPR	Char	1	\$X5712X.	\$1.	9f. Feel depressed
33	FEELWORN	Char	1	\$X5712X.	\$1.	9g. Feel worn/washed out
34	FEELHAP	Char	1	\$X5712X.	\$1.	9h. Feel happy/cheerful
35	FEELTIR	Char	1	\$X5712X.	\$1.	9i. Feel tired/fatigued
36	INSOCIAL	Char	1	\$X5712X.	\$1.	Interfere social activity

Num	Variable	Type	Len	Format	Informat	Label
37	SICKEASY	Char	1	\$X3673X.	\$1.	11a. Sick easier
38	HEALTHY	Char	1	\$X3673X.	\$1.	11b. Healthy as anybody
39	WORSE	Char	1	\$X3673X.	\$1.	11c. Expecting worse
40	EXCLNT	Char	1	\$X3673X.	\$1.	11d. Health is excellent
41	SF36DATE_DAYS	Num	8			Date SF-36 Performed (recode: number of days after consent)

Data Set Name: sgr.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	PROTSEG	Char	1	\$1.	\$1.	Protocol Segment
4	DECLANC	Char	1	\$X1457X.	\$1.	Decline in ANC
5	GIVEGF	Char	1	\$X1457X.	\$1.	Growth Factor Given
6	DONDEC	Char	1	\$X1457X.	\$1.	Donor Chimerism Decline
7	PERDONOR	Num	8	2.	2.	Percent Donor
8	SGFDATE_DAYS	Num	8			Secondary Graft Fail Date (recode: number of days after consent)
9	TCCHIMDT_DAYS	Num	8			Date Sample Collected (recode: number of days after consent)

Data Set Name: t25.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	PROTSEG	Char	1	\$1.	\$1.	Protocol Segment
4	VISNO	Char	4	\$4.	\$4.	Visit Number
5	TXFEVER	Char	1	\$X18341X.	\$1.	Fever
6	T25FATIG	Char	1	\$X32112X.	\$1.	Fatigue
7	ALRGCRXN	Char	1	\$X24061X.	\$1.	Allergic Reaction
8	ANAPHYLX	Char	1	\$X24062X.	\$1.	Anaphylaxis
9	ORLMUCOS	Char	1	\$X23105X.	\$1.	Oral Mucositis
10	TXNAUSEA	Char	1	\$X23126X.	\$1.	Nausea
11	VOMIT	Char	1	\$X23124X.	\$1.	Vomiting
12	DIARRHEA	Char	1	\$X23127X.	\$1.	Diarrhea
13	T25ABDPN	Char	1	\$X32113X.	\$1.	Abdominal pain
14	T25ANORX	Char	1	\$X31946X.	\$1.	Anorexia
15	T25CNSTP	Char	1	\$X32114X.	\$1.	Constipation
16	T25DYSGS	Char	1	\$X1457X.	\$1.	Dysgeusia
17	T25DSPEP	Char	1	\$X32116X.	\$1.	Dyspepsia
18	T25GASTR	Char	1	\$X31947X.	\$1.	Gastroenteritis
19	CYSTNINF	Char	1	\$X23113X.	\$1.	Cystitis Noninfective
20	ACKIDINJ	Char	1	\$X23859X.	\$1.	Acute Kidney Injury
21	CHKIDDIS	Char	1	\$X24063X.	\$1.	Chronic Kidney Disease
22	HEMORRHG	Char	1	\$X23114X.	\$1.	Hemorrhage
23	ORGSYHEM	Char	1	\$X18324X.	\$1.	Organ System Hemorrhage
24	HYPOTEN	Char	1	\$X23106X.	\$1.	Hypotension
25	HYPERTSN	Char	1	\$X23115X.	\$1.	Hypertension
26	CRDARRHY	Char	1	\$X23116X.	\$1.	Cardiac Arrhythmia
27	CRDARRSP	Char	50	\$50.	\$50.	Cardiac Arrhythmia Specif
28	MYOCDINF	Char	1	\$X24064X.	\$1.	Myocardial Infarction
29	LFVTSYDF	Char	1	\$X23107X.	\$1.	Left Vent Syst Dysfunct
30	PERCRDEF	Char	1	\$X23117X.	\$1.	Pericardial Effusion
31	RSTCDMYP	Char	1	\$X23118X.	\$1.	Restrictive Cardiomyopath
32	T25HFAIL	Char	1	\$X31944X.	\$1.	Heart Failure
33	T25PERED	Char	1	\$X31945X.	\$1.	Peripheral Edema
34	SOMNOLN	Char	1	\$X23119X.	\$1.	Somnolence
35	TXSEIZR	Char	1	\$X23108X.	\$1.	Seizure
36	NEURPTHY	Char	1	\$X24065X.	\$1.	Neuropathy

Num	Variable	Type	Len	Format	Informat	Label
37	NEURTYSP	Char	1	\$X24066X.	\$1.	Neuropathy Type Specify
38	T25ANXTY	Char	1	\$X31940X.	\$1.	Anxiety
39	T25CNFUS	Char	1	\$X32118X.	\$1.	Confusion
40	T25DEPRS	Char	1	\$X31941X.	\$1.	Depression
41	T25DIZZY	Char	1	\$X32119X.	\$1.	Dizziness
42	T25HDACH	Char	1	\$X31942X.	\$1.	Headache
43	T25INSOM	Char	1	\$X32120X.	\$1.	Insomnia
44	T25PRES	Char	1	\$X31943X.	\$1.	PRES Syndrome
45	T25SYNCP	Char	1	\$X32122X.	\$1.	Syncope
46	THRMBPUR	Char	1	\$X23120X.	\$1.	Thrombocytopenic Purpura
47	T25ANEM	Char	1	\$X32233X.	\$1.	Anemia
48	T25NEUTR	Char	1	\$X4977X.	\$1.	Neutropenia
49	T25THROM	Char	1	\$X18884X.	\$1.	Thrombocytopenia
50	CAPLKSYN	Char	1	\$X23121X.	\$1.	Capillary Leak Syndrome
51	THROMBEV	Char	1	\$X24078X.	\$1.	Thromboembolic Event
52	T25ARTHR	Char	1	\$X32125X.	\$1.	Arthralgia
53	T25MYALG	Char	1	\$X32125X.	\$1.	Myalgia
54	T25MUSCL	Char	1	\$X32126X.	\$1.	Muscle Weakness
55	TXHYPXIA	Char	1	\$X23104X.	\$1.	Hypoxia
56	TXDYSRNA	Char	1	\$X23109X.	\$1.	Dyspnea
57	T25COUGH	Char	1	\$X32127X.	\$1.	Cough
58	T25PLEFU	Char	1	\$X31951X.	\$1.	Pleural Effusion
59	T25SINUS	Char	1	\$X31952X.	\$1.	Sinusitis
60	T25SRTHT	Char	1	\$X31953X.	\$1.	Sore Throat
61	T25HYPRC	Char	1	\$X32128X.	\$1.	Hypercalcemia
62	HYPRGLYC	Char	1	\$X24071X.	\$1.	Hyperglycemia
63	T25HYPOG	Char	1	\$X32129X.	\$1.	Hypoglycemia
64	T25HYPOK	Char	1	\$X32130X.	\$1.	Hypokalemia
65	T25HYPON	Char	1	\$X32131X.	\$1.	Hyponatremia
66	T25HYPTH	Char	1	\$X36933X.	\$1.	Hyperthyroidism
67	T25HYPOT	Char	1	\$X36933X.	\$1.	Hypothyroidism
68	T25HEAR	Char	1	\$X32133X.	\$1.	Hearing Loss
69	T25PRURI	Char	1	\$X32134X.	\$1.	Pruritus
70	T25RASH	Char	1	\$X32135X.	\$1.	Rash
71	T25HYPHD	Char	1	\$X31950X.	\$1.	Hyperhidrosis
72	T25BLRVS	Char	1	\$X32136X.	\$1.	Blurred vision
73	T25CNJCT	Char	1	\$X32136X.	\$1.	Conjunctivitis
74	T25HEPAT	Char	1	\$X1457X.	\$1.	Hepatitis
75	T25LVRFL	Char	1	\$X1457X.	\$1.	Liver Failure

Num	Variable	Type	Len	Format	Informat	Label
76	T25PANCR	Char	1	\$X32137X.	\$1.	Pancreatitis
77	TXALT	Char	1	\$X5545X.	\$1.	ALT
78	TXAST	Char	1	\$X11753X.	\$1.	AST
79	TXALKPH	Char	1	\$X23122X.	\$1.	Alkaline Phosphatase
80	TXBILIRB	Char	1	\$X3854X.	\$1.	Bilirubin
81	TXJAUND	Char	1	\$X1457X.	\$1.	Jaundice
82	HEPTMGLY	Char	1	\$X1457X.	\$1.	Hepatomegaly
83	RTQUADPN	Char	1	\$X1457X.	\$1.	Right Upper Quadrant Pain
84	TXWGHTGN	Char	1	\$X1457X.	\$1.	Weight Gain >5 Percent
85	VODETIOL	Char	1	\$X1457X.	\$1.	VOD Etiology
86	GVHETIOL	Char	1	\$X1457X.	\$1.	GVHD Etiology
87	GVHBIOP	Char	1	\$X1822X.	\$1.	GVHD Biopsy
88	GVHDOPP	Char	1	\$X4472X.	\$1.	GVHD Doppler
89	INFETIOL	Char	1	\$X1457X.	\$1.	Infection Etiology
90	OTHETIOL	Char	1	\$X1457X.	\$1.	Other Etiology
91	OTHBIOP	Char	1	\$X1822X.	\$1.	Other Biopsy
92	OTHDOPP	Char	1	\$X4472X.	\$1.	Other Doppler
93	UNKETIOL	Char	1	\$X1457X.	\$1.	Unknown Etiology
94	OTHETSP	Char	50	\$50.	\$50.	Other Etiology Specify
95	T25IALRG	Char	1	\$X32138X.	\$1.	Infusion Allergy
96	T25ICRDA	Char	1	\$X23116X.	\$1.	Infusion Arrhythmia
97	T25IFEVR	Char	1	\$X18341X.	\$1.	Infusion Fever
98	T25IHYP0	Char	1	\$X23106X.	\$1.	Infusion Hypotension
99	T25IHYP1	Char	1	\$X23115X.	\$1.	Infusion Hypertension
100	T25IHYPX	Char	1	\$X23104X.	\$1.	Infusion Hypoxia
101	T25IRIGR	Char	1	\$X32139X.	\$1.	Infusion Rigors or Chills
102	T25IVOMT	Char	1	\$X23124X.	\$1.	Infusion Vomiting
103	T25ENCEP	Char	1	\$X1457X.	\$1.	Encephalopathy
104	T25PARAL	Char	1	\$X1457X.	\$1.	Paralysis-Muscle Weakness
105	T25PERCD	Char	1	\$X32117X.	\$1.	Pericarditis
106	T25INTOB	Char	1	\$X1457X.	\$1.	Intestinal obstruction
107	T25CREAT	Char	1	\$1.	\$1.	Serum Creatinine
108	T25TMLYS	Char	1	\$X1457X.	\$1.	Tumor Lysis Syndrome
109	T25VISLS	Char	1	\$X1457X.	\$1.	Sudden Vision Loss
110	T25PNEUM	Char	1	\$1.	\$1.	Pneumonia
111	T25SAEDF	Char	1	\$X1457X.	\$1.	SAE Definition Met
112	T25SAESP	Char	100	\$100.	\$100.	SAE Definition Specify
113	TXYEVLDT_DAYS	Num	8			Toxicity Evaluation Date (recode: number of days after consent)

Data Set Name: txp.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	PROTSEG	Char	1	\$1.	\$1.	Protocol Segment
4	VISNO	Char	4	\$4.	\$4.	Visit Number
5	CMVSTAT	Char	1	\$X1579X.	\$1.	CMV Status
6	TXDTPXP_DAYS	Num	8			Stem Cell Infusion Date (recode: number of days after consent)
7	CONDNGDT_DAYS	Num	8			Conditioning Date (recode: number of days after consent)

Data Set Name: vdf.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	PROTSEG	Char	1	\$1.	\$1.	Protocol Segment
4	VISNO	Char	4	\$4.	\$4.	Visit Number
5	VDFOCCUR	Char	1	\$X1457X.	\$1.	Visit Occur
6	VDFVSTYP	Char	1	\$X55832X.	\$1.	Visit Type
7	VDFDELAY	Char	1	\$X1457X.	\$1.	Visit Delay
8	VDFDLYRS	Char	2	\$X56403X.	\$2.	Visit Delay Reason
9	VDFREAS	Char	2	\$X55870X.	\$2.	No Visit Reason
10	VDFVISDT_DAYS	Num	8			Visit Date (recode: number of days after consent)

Data Set Name: woc.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ANONID	Char	7			Randomized Subject ID
2	PROT	Char	5	\$5.	\$5.	Protocol
3	WOCSTP	Char	1	\$X1457X.	\$1.	Study Procedures
4	WOCISD	Char	1	\$X1457X.	\$1.	Rec Inves Study Drug
5	WOCFRB	Char	1	\$X1635X.	\$1.	Future Res Blood SP
6	WOCFBM	Char	1	\$X1635X.	\$1.	Future Res BM
7	WOCPDA	Char	1	\$X1457X.	\$1.	Provide Data
8	WOCURSAM	Char	1	\$X1635X.	\$1.	Urine Sample
9	WOCSTPDT_DAYS	Num	8			Study Procedures Date (recode: number of days after consent)
10	WOCISDDT_DAYS	Num	8			Rec Inves Study Drug Date (recode: number of days after consent)
11	WOCFRBDT_DAYS	Num	8			Future Res Blood SP Date (recode: number of days after consent)
12	WOCFBMDT_DAYS	Num	8			Future Res BM Date (recode: number of days after consent)
13	WOCPDADT_DAYS	Num	8			Provide Data Date (recode: number of days after consent)
14	WOCUSMDT_DAYS	Num	8			Urine Sample Date (recode: number of days after consent)